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Abstract 
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is an integral multidomain 
membrane protease involved in extracellular matrix remodelling. No longer recognized 
solely as a destructive enzyme, MT1-MMP proteolytic and non-proteolytic activities are 
involved in a variety of cellular processes. I hypothesized that the diverse functions of MT1-
MMP are dependent on domain-specific binding partner interactions that elicit a cellular 
response. Using a combination of co-immunoprecipitation and mass spectrometry, 248 
unique proteins were isolated in MT1-MMP variant expressing MCF-7 cells. Newly 
identified binding partners suggest potential roles of MT1-MMP in the nucleus, endoplasmic 
reticulum, cytoplasm, and plasma membrane. Additionally, the cytoplasmic domain of MT1-
MMP attenuates canonical transforming growth factor beta (TGF-β) signalling through an 
unknown mechanism. The results of this proteomic study add proteins to a growing catalogue 
of binding partners involved in proper localization and function of MT1-MMP. 
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Summary for Lay Audience 
The extracellular matrix (ECM) is an interconnected network of proteins that provides 
structural support to cells, tissues, and organ systems. For cells, the building blocks of life, to 
migrate to new places within a growing organism, the ECM needs to be remodelled. It is 
important to note that migration is necessary for proper development and function, but 
abnormal cell migration is involved in various pathologies. Matrix metalloproteinases 
(MMPs) are proteins secreted by the cell into the ECM, where they function to break down 
the ECM so the cell can move freely. There are many types of MMPs that can collectively 
degrade all the different parts of the ECM. In my project, I studied membrane-type 1 matrix 
metalloproteinase (MT1-MMP). Early research deemed MT1-MMP a destructive enzyme 
observed in cancerous tissue. However, MT1-MMP not only degrades the ECM so the cell 
can move, but part of this protein extends into the cell (cytoplasmic domain), where it is 
observed to communicate to the cell when and where to migrate. For this reason, MT1-MMP 
is described as a multifunctional protease. The purpose of my research was to further 
investigate the function of MT1-MMP, more specifically through its interaction with other 
proteins. Here, 248 proteins were identified that associate with MT1-MMP in breast cancer 
cells. These newly identified proteins point to possible novel interactions and functions of 
MT1-MMP throughout the cell, not just its role as an enzyme. Additionally, removal of the 
cytoplasmic domain induces transforming growth factor beta (TGF-β) signalling, an 
important regulator of cellular processes. TGF-β signalling, in addition to having critical 
embryonic roles, has dual functions in tumours, acting either as a suppressor or activator. 
Understanding what MT1-MMP interacts with is critical due to its involvement in many 
important processes in development, wound healing, and disease. 
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1 INTRODUCTION 
1.1 Extracellular matrix 
The extracellular matrix (ECM) is a heterogenous, three-dimensional network of secreted 
macromolecules that provides structural support to the embedded cells. Composed 
primarily of water, polysaccharides, and proteins, the composition and structure of the 
ECM influences the function of cells in tissues (Theocharis et al., 2016). Matrix 
components bind to each other as well as cell adhesion receptors, typically integrins, with 
which cells integrate signals from the ECM. It is important to note that cell-ECM 
interactions are reciprocal. All cell types locally synthesize and secrete ECM 
macromolecules, which in turn can influence the behaviour of surrounding cells (Kim et 
al., 2011). For this reason, the ECM is important for cellular growth, migration, 
differentiation, survival, homeostasis, and morphogenesis (Clause and Barker, 2013; 
Frantz et al., 2010).  
Structurally, the ECM can be classified into two components: the interstitial matrix and 
basement membrane. These two domains share a basic structure defined by a collagen 
scaffold, but the types of collagen and resulting three-dimensional structure are 
drastically different (Bosman and Stamenkovic, 2003). The interstitial matrix is primarily 
deposited by stromal cells and composed of fibrillar collagens, proteoglycans, and 
glycoproteins that contribute to the tensile strength of the tissue (Egeblad et al., 2010; Lu 
et al., 2012). The basement membrane is a sheet-like barrier produced jointly by 
epithelial, endothelial, and stromal cells. Composed primarily of type IV collagen, 
laminins, fibronectin, and linker proteins, the basement membrane is much more compact 
and less porous than the interstitial matrix (Egeblad et al., 2010; Lu et al., 2012). 
Separating epithelial cells from the surrounding stroma, the basement membrane is a 
specialized form of ECM that is not only crucial to maintain cell polarity, but also serves 
to support and inhibit the movement of cells (Kalluri, 2003; Pöschl et al., 2004). The 
mechanisms involved in the process of cell movement are well understood. In brief, a 
migrating cell will become polar in which actin-based membrane protrusions will adhere 
to specific ECM substrate through cell surface integrins, giving polarity to the cell 
(leading edge). As the cell advances, posterior focal adhesions will detach to facilitate 
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forward movement of the cell body (trailing edge) (Trepat et al., 2012). Coordinated 
movement of the cell is primarily guided by cell-ECM and cell-cell cues (Reig et al., 
2014). With this in mind, the ECM is not only a physical scaffold supporting the cell, but 
also a reservoir of biologically active molecules that can modulate cell movement (Chirco 
et al., 2006; Egeblad and Werb, 2002).  
Independent of its structural function, the biochemical properties of the ECM rely on its 
association with growth factors, cytokines, and chemokines within the matrix that allow 
cells to sense and interact with their environment through various signal transduction 
cascades. Signalling molecules that elicit a cellular response can be sequestered within 
the ECM, limiting diffusion and maintaining homeostasis. Then, at a developmentally or 
physiologically relevant time, these molecules can be locally released from the matrix 
through proteolytic processing (Theocharis et al., 2016). For example, vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 2 bind to heparan 
sulfate proteoglycans, and are sequestered in the ECM (Ortéga et al., 1998; Robinson and 
Stringer, 2001; Walker et al., 1994). This retention creates a chemical gradient important 
during development for proper cell differentiation (Hynes, 2009). The interaction 
between FGF-2 and heparan sulfate is also required for binding to, and stabilization of, 
the FGF receptors (Rapraeger et al., 1991; Schlessinger et al., 2000; Yayon et al., 1991). 
Through sequestering and release of signalling molecules, the ECM can indirectly 
influence cell behaviour. However, ECM proteins themselves can serve as ligands for cell 
receptors, thus directly affecting cell function. Laminin, an integral ECM glycoprotein, 
contains multiple epidermal growth factor (EGF)-like domains which may bind to EGF 
receptors (EGFR) (Engel, 1989). When presented as soluble ligands, laminin EGF-like 
domains were able to modulate signalling through EGFR (Panayotou et al., 1989; Schenk 
et al., 2003). Many such domains are found within ECM proteins in various arrangements 
and combinations so it is hypothesized that these domains can be released by proteolysis 
to act as soluble ligands (Hynes, 2009).  
Cells are constantly remodelling the ECM through synthesis, degradation, and subsequent 
reassembly of matrix proteins – especially during cell migration and invasion. As 
described, the basement membrane directly underlies epithelial and endothelial cells 
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where it functions as a barrier of cell invasion. With a thickness of approximately 100-
300 nm, the collagen IV scaffold of the basement membrane is densely compact with a 
pore size of approximately 50 nm between fibers (Abrams et al., 2000). As the typical 
permissive size for cell movement is 2 μm, the ECM must be remodelled for migration to 
occur, a process that includes protease-mediated degradation (Rowe and Weiss, 2009). 
During embryogenesis, remodelling occurs during large-scale migration events such as 
gastrulation, neurulation, and other processes in which cells undergo epithelial-
mesenchymal transition (EMT). All of these involve disruption of cell-cell and cell-ECM 
adhesion as well as turnover of the ECM (Ohta et al., 2010). The mechanisms mediating 
ECM remodelling are also associated with many diseases including breast cancer, in 
which excessive ECM degradation seemingly allows the invasion of epithelial cells 
(Bonnans et al., 2014). Important for cell migration and invasion during development, but 
also unregulated in various pathologies, the ECM is a dynamic structure that is 
remodelled and degraded by proteases.  
The importance of ECM remodelling during development has been studied for decades. 
The first vertebrate collagenolytic factor was identified by Gross and Lapiere (1962) in 
tadpole tissues (skin, gut, and gills) undergoing metamorphosis, establishing the field of 
protease-mediated ECM remodelling research. To date, the MEROPS database has 
identified over 600 individual peptidases and 1600 inhibitors in the human degradome. 
Based on the nucleophile involved in catalysis, the degradome can be divided into 
aspartic proteases, cysteine proteases, metalloproteases, mixed proteases, serine 
proteases, and threonine proteases (Figure 1) (Rawlings et al., 2014). Cysteine, serine, 
and threonine proteases utilize their respective amino acid side chains as a nucleophile, 
while mixed proteases are capable of using a combination of the three (Rawlings et al., 
2014). In contrast, aspartic proteases and metalloproteases use an activated water  
molecule to mediate the nucleophilic attack of a peptide bond (James, 2004; Murphy and 
Nagase, 2008). Although proteases in each clan contain the same nucleophile in the 
catalytic site, the molecular structures, catalytic mechanism, and sequence homology can 
be very different between individual proteases (Rawlings et al., 2014). Proteases are 
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Figure 1. Classification of proteases in the human degradome  
To date, MEROPS database has identified over 600 known and putative peptidases 
within the human degradome. They can be classified into six groups – aspartic, cysteine, 
mixed, serine, threonine, and metalloproteases – as based on the nucleophile involved in 
catalysis. Aspartic proteases and metalloproteases activate a water molecule to cleave a 
peptide bond. In contrast, serine, cysteine, and threonine proteases utilize their 
corresponding amino acid side chains, with mixed proteases capable of using a 
combination of the three (Rawlings et al., 2014).  
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further divided into families that share significant sequence homology to a prototypical 
representative of the family, usually the peptidase that has been most studied (Rawlings 
et al., 2014). Matrix metalloproteinases are a family of proteases that have been well-
studied because they are the primary enzymes involved in ECM remodelling. 
1.2 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs), or matrixins, are a subfamily of zinc-dependent 
endopeptidases with amino acid sequence similarity to the catalytic domain of human 
fibroblast collagenase 1 (MMP-1) (Rawlings et al., 2014). In total, there are 24 matrixin 
genes in the human genome, but only 23 unique MMP proteins due to a duplication of 
MMP23. As members of the metzincin superfamily of proteases, the catalytic domain 
contains a zinc-binding motif (HEXXHXXGXXH) and a conserved methionine (“Met-
turn”) eight residues downstream (Bode et al., 1993; Murphy et al., 1991). This sequence 
creates an active site in which the three histidines ligated to a catalytic Zn2+ ion rest on 
the conserved “Met-turn” - a hydrophobic base - for further support of the structure. The 
glutamate within the zinc-binding motif aids in polarizing a Zn2+-bound water molecule. 
During a series of transition states, the Zn2+-bound water executes a nucleophilic attack 
of the target peptide’s carbonyl carbon, resulting in the breakdown of the peptide bond 
between the carboxyl group and amino group of two linked amino acids, as well as the 
release of a water molecule (Bode et al., 1999; Jacobsen et al., 2010; Park et al., 2003; 
Pelmenschikov and Siegbahn, 2002). MMPs are distinguished from other metzincins by 
their synthesis as pre-proenzymes with a “cysteine switch” motif (PRCGXPD), which 
maintains the newly translated enzyme in a latent state (Figure 2a) (Van Wart and 
Birkedal-Hansen, 1990). The signal peptide of a pre-proMMP is removed during 
translation, but the proMMP remains inactive due to the cysteine sulfhydryl group within 
the pro-domain chelating the active site Zn2+ (Van Wart and Birkedal-Hansen, 1990). 
Disruption of the zinc-thiol interaction is required for the zymogen to acquire activity, 
typically by protease-mediated removal of the pro-domain (Ra and Parks, 2007; Van 
Wart and Birkedal-Hansen, 1990). However, proMMPs can also be activated by various  
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Figure 2. Classification of matrix metalloproteinases within the human degradome 
(a) Due to the diversity of the human degradome, enzymes are categorized following the 
ranking scheme of clan, subclan, family, and subfamily. Clan MA: Clan MA contains a 
variety of metallopeptidases identified by an HEXXH motif. Two histidines stabilize a 
catalytic Zn2+ ion while a nearby glutamic acid polarizes the Zn2+-bound water molecule 
to cleave the peptide. Subclan MA(M): Clan MA is further divided into subclan MA(M) 
in which these peptidases are synthesized as inactive zymogens. Family M10: 
Metzincins, classified as family M10, contain the motif HEXXHXXGXXH and a 
methionine located 7 amino acids C-terminal to the last His. Expanding upon the clan 
MA motif, the third His is involved in stabilizing the catalytic Zn2+. The conserved 
methionine forms a hydrophobic base - a structure identified as a “Met-turn” - which 
supports the catalytic site (Bode et al., 1993). The metzincin family includes various 
subfamilies differing in the mechanism of activation. Subfamily M10A: Matrix 
metalloproteases (MMPs), termed matrixins as part of subfamily M10A, are a mosaic 
group of 23 unique proteins that remain inactive due to a “cysteine switch” (Van Wart 
and Birkedal-Hansen, 1990). Synthesized as pre-proenzymes, an inhibitory pro-domain 
contains a PRCGXPD motif in which the cysteine sulfhydryl group chelates the active 
site Zn2+, preventing interaction with a water molecule. (b) Structure: Save for MMP-7, 
MMP-23, and MMP-26, matrix metalloproteases typically share a common core structure 
of a propeptide, catalytic domain, linker region, and hemopexin domain.
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9 
ectopic mechanisms that perturb the conformation or free the thiol (Springman et al., 
1990; Van Wart and Birkedal-Hansen, 1990). 
Matrix metalloproteinases are classified by two independent characteristics: substrate 
preference and cellular localization. They can be divided into collagenases (MMP-1, -8, 
and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, and -11), matrilysins 
(MMP-7 and -26), membrane-bound (MMP-14, -15, -16, -17, -24, and -25), and other 
MMPs (MMP-12, -19,  -20, -21, -23, -27, and -28) as based on domain organization and 
ECM substrate affinity. Each MMP has distinct yet overlapping substrate specificities, 
but together they can process virtually all ECM proteins (Sternlicht and Werb, 2001). 
Because of this, a more common classification of MMPs is based on their cellular 
localization. A majority of MMPs are soluble and commonly secreted into the ECM as 
zymogens (proMMPs). In contrast, membrane-type MMPs are anchored to the cell 
membrane after their pro-domains are removed in the Golgi, and thus are proteolytically 
active. Membrane-type 1, 2, 3, and 5 MMPs contain a type 1 transmembrane domain 
followed by a cytoplasmic domain, whereas MT4-MMP and MT6-MMP are 
glycosylphosphatidylinositol-anchored to the plasma membrane (Itoh et al., 1999; 
Kojima et al., 2000; Sato et al., 1994). Typically, MMPs share a common structure: a 
propeptide of about 80 amino acids, a catalytic domain of about 170 amino acids, a linker 
or hinge region of variable length, and a hemopexin domain of about 200 amino acids 
(Figure 2b). Exceptions include MMP-7, MMP-23, and MMP-26, which lack the linker 
peptide and hemopexin domain (Murphy and Nagase, 2008; Nagase et al., 2006). MMP-
23 uniquely contains a C-terminal cysteine rich immunoglobulin-like domain after the 
catalytic domain (Gururajan et al., 1998; Park et al., 2000).  
1.3 MMP regulation 
Due to an overlap in substrate specificity, the biological function of an individual MMP 
is often dictated by its differential pattern of expression as compared to other similar 
MMPs (Sternlicht and Werb, 2001). Although expression varies during embryogenesis, 
MMP transcription in healthy adult tissue is restricted to low levels, save for wound 
healing or immune response, by a combination of inhibitory mechanisms (Moore and 
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Crocker, 2012; Sternlicht and Werb, 2001). MMP expression can be influenced by a 
variety of cytokines, growth factors, hormones, and chemical agents, leading to cell-type 
specific responses (Mauviel, 1993). For example, transforming growth factor-β (TGF-β) 
1 induces MMP-9 expression in oral squamous cell carcinoma (Sun et al., 2008). In 
contrast, inhibition of TGF-β in mice following myocardial infarction results in increased 
MMP-9 expression in ventricular myocardium (Frantz et al., 2008). Similar to 
expression, which can be cell-type specific, growth factor responses can also be MMP-
specific; some MMPs have a TGF-β1 inhibitory element in their promoter, whereas 
others, like MMP-2, do not (Cui et al., 2017). In many cases, stimulatory or suppressive 
factors modulate the expression/activation of c-fos and c-jun, which bind activator protein 
(AP-1) sites within MMP promoters.  
Additional to transcriptional regulation, like other proteolytic enzymes, MMPs are 
synthesized as zymogens and are post-translationally regulated. The inhibitory pro-
domain of proMMPs is removed either intra- or extracellularly to expose the catalytic 
domain. Membrane-type MMPs, as well as MMP-11, -21, -23, and -28, contain a target 
sequence between the propeptide and catalytic domain, which is commonly cleaved by 
furin in the trans-Golgi network (Pei and Weiss, 1995; Ra and Parks, 2007). Secreted 
soluble MMPs that lack the furin-susceptible cleavage site are activated outside of the 
cell by serine proteases and other MMPs. Treatment with heavy metals, oxidants, 
disulfide compounds, and sulfhydryl-alkylating agents can also disrupt the inhibitory pro-
domain cysteine switch, thus uncovering the catalytic domain (Van Wart and Birkedal-
Hansen, 1990).  
In addition to pro-domain inhibition of proteolytic function, another level of MMP 
regulation relies on compartmentalization of MMPs to specific regions of the pericellular 
environment. Localization to the plasma membrane is straightforward for membrane-type 
MMPs, but soluble MMPs can also be anchored to maintain a locally high concentration 
at the cell surface. Protein-protein interactions that compartmentalize soluble MMPs 
include MMP-1 to α2β1 integrin (Dumin et al., 2001; Stricker et al., 2001), MMP-2 to 
αVβ3 integrin (Brooks et al., 1998) and MMP-9 to cluster of differentiation 44 (CD44) 
(Yu and Stamenkovic, 2000). Many docking mechanisms have not been definitively 
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proven, though it is likely that other secreted MMPs are localized in a similar manner 
(Parks et al., 2004; Ra and Parks, 2007). Confinement of MMPs to the cell surface is also 
important for pro-enzyme activation by other proteases and increased probability of 
substrate proteolysis. Additionally, MMPs have a localization to the leading edge of 
migrating and invading cells. Migrating human colon adenocarcinoma L-10 cells express 
MT1-MMP and MMP-2 on their leading edges to remodel the gelatin substrate on which 
they were seeded. This migration was ablated by treatment with BB-94, a broad-spectrum 
inhibitor of MMP proteolytic function (Nabeshima et al., 2000). Similarly, MT1-MMP as 
well as MMP-2 and MMP-9 concentrate at invadopodia, specialized actin-based 
protrusions commonly associated with invasive tumour cells (Bowden et al., 1999; 
Buccione et al., 2004; Chen, 1989; Clark and Weaver, 2008; Linder, 2007; Nakahara et 
al., 1997).  
A further mechanism of MMP regulation involves blocking proteolytic function by 
endogenous inhibitors within the ECM. Tissue inhibitors of metalloproteinases (TIMP) 
are a family of secreted proteins that include TIMP-1, -2, -3, and -4 in humans. The 
TIMP N-terminal domain binds non-covalently to the active catalytic domain of MMPs, 
thus inhibiting the proteolytic function of the latter. The C-terminal domain plays a role 
independent of catalytic inhibition and can bind various ECM and cell-surface proteins to 
regulate cell survival and migration (Moore and Crocker, 2012; Stetler-Stevenson, 2008; 
Tuuttila et al., 1998). The four mammalian TIMPs are able to bind each of the 23 
different MMPs, but with different efficacies (Bourboulia and Stetler-Stevenson, 2010). 
This interaction occurs in a 1:1 ratio of TIMP:MMP, but depending on the stoichiometry 
of these proteins in the ECM, TIMPs can either inhibit or activate MMPs (section 1.4.1). 
Another endogenous inhibitor shown to negatively regulate MT1-MMP, MMP-2, and 
MMP-9 proteolytic activity and/or expression is reversion-inducing cysteine-rich protein 
with Kazal motifis (RECK), a GPI-anchored protein (Chang et al., 2008; Oh et al., 2001; 
Simizu et al., 2005; Takahashi et al., 1998). The Kazal motifs, for which RECK is named, 
are serine protease inhibitor-like domains believed to suppress MMP proteolytic function 
(Takahashi et al., 1998). Interestingly, TIMP-2 can bind α3β1 integrin on the surface of 
human endothelial cells leading to increased RECK expression, suggesting that these 
inhibitors may act in a coordinated manner (Oh et al., 2004). While TIMPs and RECK 
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are the most commonly studied endogenous inhibitors that reversibly bind MMPs, others 
such as α2-macroglobulin can irreversibly clear MMPs from the ECM (Tchetverikov et 
al., 2003). MMP•α2-macroglobulin complexes are removed by scavenger receptor-
mediated endocytosis (Sternlicht and Werb, 2001). Altogether, MMP proteolytic activity 
can be regulated by TIMPs, RECK, and other endogenous inhibitors, which too can differ 
in their transcriptional regulation and tissue-specific expression patterns (Sternlicht and 
Werb, 2001).  
1.4 Membrane-type 1 matrix metalloproteinase 
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is the commonly used alias of 
MMP14 employed by the broader scientific community. Of all MMPs, MT1-MMP is 
well characterized due to its importance during development as well as many human 
pathologies. MT1-MMP is indispensable for embryonic development as it is the only 
MMP that is lethal when knocked out in mice (Holmbeck et al., 1999). These knockout 
mice exhibit craniofacial dysmorphism, dwarfism, and arthritis due to an ablation in 
collagenolytic activity crucial during skeletal and extraskeletal tissue development 
(Holmbeck et al., 1999). As a collagenase, MT1-MMP can degrade integral ECM 
substrates such as collagen types I, II, and III, as well as vitronectin and laminin 1 
(Ohuchi et al., 1997). While MT1-MMP expression is common in development, it is low 
or negligible in healthy adult cells. However, cancerous cells may reactivate the 
developmental transcriptional programming of MMPs since MT1-MMP is present in 
mesenchymal cancers, sarcomas, and mesotheliomas as well as primary human breast 
cancers (Li et al., 2015; Lodillinsky et al., 2016; Marchesin et al., 2015; Turunen et al., 
2017). As there is no preeminent genetic link between MT1-MMP and cancer, this 
suggests that the role(s) played by MT1-MMP in cancerous tissue is not due to a 
mutation. For this reason, the extracellular proteolytic activity of MT1-MMP has been 
well-studied due to its role in ECM remodelling during development as well as cell 
migration and invasion. However, MT1-MMP functions on multiple levels: the 
proteolysis of ECM molecules (section 1.4.1), MT1-MMP interaction with various 
extracellular (section 1.4.2) and intracellular (section 1.4.3) binding partners, proteolysis 
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of intracellular molecules (section 1.4.4), and as a possible transcription factor 
(section1.4.5); as summarized in Figure 3 (Knapinska and Fields, 2019).  
1.4.1 Proteolysis of ECM molecules 
The most well-described proteolytic function of MT1-MMP is not related to degradation 
of structural ECM molecules, but the activation of proMMP-2 in collaboration with 
TIMP-2. As mentioned, MT1-MMP is embedded in the plasma membrane in an active 
form with its pro-domain already removed. Two MT1-MMP molecules homodimerize 
through their hemopexin and transmembrane domains (Itoh et al., 2001, 2008). A 
TIMP-2 molecule can then bind via its N-terminal domain to the catalytic domain of one 
of these MT1-MMP molecules, thus inhibiting its proteolytic activity (Strongin et al., 
1995). At this time, the hemopexin domain of a nearby proMMP-2, which has affinity for 
the exposed TIMP-2 C-terminal domain, binds to it, forming a (MT1-MMP)2•TIMP-2• 
proMMP-2 quaternary complex (Itoh and Seiki, 2006). The uninhibited MT1-MMP 
within this complex is then able to cleave the pro-domain of MMP-2, initiating the 
activation of this MMP-2 molecule (Will et al., 1996). Once activated, MMP-2 can either 
be released into the ECM, remain bound to TIMP-2 via its hemopexin domain, or remain 
bound to TIMP-2, but subsequently inhibited by another TIMP-2 molecule (Itoh et al., 
1998b). This activation mechanism is dependent on the precise stoichiometry of MMPs 
and TIMP-2 in the ECM.  
The significance of this mechanism of MT1-MMP-mediated MMP-2 activation is related 
to their different enzymatic capabilities. MMP-2, but not MT1-MMP, is able to degrade 
type IV collagen, a major component of the basement membrane (Okada et al., 1990). 
This MT1-MMP/MMP-2 mediated cleavage of the basement membrane plays a role in 
the growth and invasion of epithelial cancer cells in vivo (Taniwaki et al., 2007). It was 
hypothesized that the sole function of MT1-MMP in tumour invasion was proMMP-2 
activation (Ellerbroek and Stack, 1999; Seiki, 1999). However, MMP-2 deficient mice do 
not show the same severe developmental defects as MT1-MMP null mice, suggesting 
MT1-MMP has additional biological functions (Itoh et al., 1998a).  
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Figure 3. Domain-specific functions of membrane-type 1 matrix metalloproteinase 
Research has identified key domains of MT1-MMP necessary for its proper structure, 
localization, as well as various roles in ECM remodelling and cell signalling. 
Simplistically, MT1-MMP is composed of an extracellular catalytic domain, a linker 
region, and a hemopexin domain, followed by a transmembrane domain and intracellular 
cytoplasmic tail. Altogether, the diverse functions of membrane-type 1 matrix 
metalloproteinase are highlighted (Knapinska and Fields, 2019). 
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MT1-MMP is not only involved in initiating cell movement through ECM degradation, 
but also maintaining migration by cleaving ECM molecules that function as ligands in 
cell signalling. When TGF-β is secreted, it is non-covalently associated with its latency 
associated peptide, forming the small latent complex (SLC) (Miyazono et al., 1993). 
Furthermore, the SLC needs to associate with the latent TGF-β binding protein (LTBP) 
for proper secretion (Miyazono et al., 1991). Ultimately, MT1-MMP mediated cleavage 
of TGF-β from LTBP plays a role in activating TGF-β signalling. MT1-MMP activation 
of TGF-β1 has been associated with upregulation of CUTL1 and WNT5A to induce EMT 
in prostate cancer cells (Nguyen et al., 2016). Furthermore, free TGF-β can increase the 
expression of MT1-MMP, facilitating positive feedback via mothers against 
decapentaplegic (SMAD) 3/4 induction of SNAIL in other cancer phenotypes (Ota et al., 
2009; Shields et al., 2011, 2012). 
Additionally, MT1-MMP localization at the plasma membrane positions it to cleave 
various other cell-surface molecules.  For example, solubilization of extracellular matrix 
metalloproteinase inducer (EMMPRIN) – a cell surface glycoprotein – by MT1-MMP not 
only increases the expression/activation of other MMPs in surrounding cancerous cells, 
but also from fibroblasts and stromal cells (Egawa et al., 2006; Sameshima et al., 2000). 
MT1-MMP can shed other biomolecules such as fibronectin, death-receptor 6, pro-
tumour necrosis factor (Tam et al., 2004), syndecan-1 (Endo et al., 2003), E-cadherin 
(Covington et al., 2006), various tetraspanins (Tomari et al., 2009), mucin 16 (Bruney et 
al., 2014), and heparin-binding epidermal growth factor (Overland and Insel, 2015). All 
of which have been associated with altered migration and invasion capabilities of 
cancerous cells. Such observations have resulted in MT1-MMP being described as pro-
invasive and pro-migratory. However, MT1-MMP has also been shown to inhibit cancer 
progression. MT1-MMP-mediated shedding of endoglin and lymphatic vessel endothelial 
hyaluronan receptor-1 (LYVE-1) inhibits angiogenesis and lymphangiogenesis, 
respectively (Hawinkels et al., 2010; Wong et al., 2016). Regardless, MT1-MMP 
functions as a potent modulator of the pericellular environment through its proteolytic 
activity.  
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1.4.2 Extracellular binding partners 
Although MT1-MMP has been implicated in cell migration, a well-defined mechanism 
remains elusive since expression of constitutively inactive MT1-MMP still results in 
increased cell migration (Bonnans et al., 2014; Hara et al., 2011). Recent focus has 
shifted from the proteolytic to non-proteolytic functions of MT1-MMP with regards to 
cell migration, specifically focusing on its hemopexin, transmembrane, and cytoplasmic 
domains.   
Migrating cells reorganize their actin cytoskeleton to form lamellipodia on the leading 
edge, a process regulated by the Rho family of GTPases. These GTPases are also 
involved in CD44 localization to lamellipodia, and by association MT1-MMP (Mori et 
al., 2002; Ridley et al., 1992). In the context of CD44 - a hyaluronan receptor - 
trafficking of MT1-MMP to the leading edge of migrating cells relies on the MT1-MMP 
hemopexin domain binding to CD44 (Mori et al., 2002). Once localized to the leading 
edge, MT1-MMP can degrade ECM molecules. Interestingly, the CD44•MT1-MMP 
complex also activates EGFR. This crosstalk between CD44•MT1-MMP and EGFR 
induces cell migration through mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) pathways via phosphorylation of extracellular 
signal-regulated kinase (ERK) 1/2 and AKT, respectively (Zarrabi et al., 2011). It has 
been observed that MT1-MMP-mediated shedding of CD44 from the membrane is 
important for enhanced cell migration (Kajita et al., 2001; Mori et al., 2002; Suenaga et 
al., 2005). Shedding of CD44 disrupts its weak interaction with the substrate, eventually 
being replaced with stronger integrin interactions that fortify migration (Cauwe et al., 
2007).  
Binding of TIMP-2 to the MT1-MMP catalytic domain abolishes its proteolytic activity, 
but TIMP-2 binding to the hemopexin domain promotes cell migration and tumour 
growth via MAPK signalling (D’Alessio et al., 2008). The rat sarcoma (RAS) – rapidly 
accelerated fibrosarcoma (RAF) – ERK1/2 cascade is induced by low, physiological 
levels of TIMP-2, further highlighting the important stoichiometry of MMPs and their 
inhibitors (D’Alessio et al., 2008; Yang et al., 2013). In contrast, another study observed 
increased ERK1/2 activation when MT1-MMP was overexpressed in COS-7, which was 
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ablated by exogenous TIMP-2 (Gingras et al., 2001). The cytoplasmic domain is involved 
in ERK activation, but there is debate whether it is solely involved or works in 
conjunction with the catalytic domain (D’Alessio et al., 2008; Gingras et al., 2001). 
Regardless, in the context of its proteolytic and non-proteolytic functions, MT1-MMP 
can associate with a variety of extracellular proteins that aid in ECM remodelling and 
promote signalling.  
1.4.3 Intracellular binding partners 
There is conflicting evidence regarding influence of the MT1-MMP cytoplasmic domain 
on protein-protein binding and its subsequent effects on cell migration, invasion, and 
signalling. However, the dileucine motif (LL) within the cytoplasmic domain is important 
for internalization of MT1-MMP through clathrin-dependent mechanisms. Caveolin-
dependent internalization has also been observed (Jiang et al., 2001; Uekita et al., 2001). 
Only 20 amino acids in length, the cytoplasmic tail does not contain sequences that 
suggest any catalytic activities (Gingras et al., 2001). However, certain residues within 
the MT1-MMP cytoplasmic tail can be post-transcriptionally modified, particularly 
phosphorylation of Tyr573 and Thr567. Src-dependent phosphorylation of Tyr573 has 
been shown to impact tumour cell migration and proliferation, but there is debate about 
its effect on MT1-MMP catalytic activity (Nyalendo et al., 2007, 2008; Wang and 
McNiven, 2012). Similarly, phosphorylation of Thr567 enhances invasion and growth of 
breast and ovarian cancers (Moss et al., 2009; Yang et al., 2017). There is sequence 
similarity between the cytoplasmic domain and integrin alpha subunits (Dedhar and 
Hannigan, 1996; Gingras et al., 2001). Further links with integrins exist as during 
mammary gland branching, the MT1-MMP cytoplasmic domain is believed to regulate 
expression and activity of β1 integrin and subsequently control cell division (Mori et al., 
2013).  
A characteristic of cancer cells is altered metabolism by increasing glycolysis even in the 
presence of adequate oxygen, termed the Warburg Effect (Warburg, 1956). The MT1-
MMP cytoplasmic domain can impact cell survival in times of metabolic stress by 
increased transcription of hypoxia-inducible factor (HIF)-1α target genes (Koziol et al., 
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2012; Sakamoto et al., 2011). During processing in the Golgi, the cytoplasmic domain 
binds to factor-inhibiting HIF-1α (FIH), recruiting its inhibitor amyloid β A4 precursor 
protein-binding family A member 3 (Mint3), thus deterring FIH-induced repression of 
HIF-1α. Once stabilized, HIF-1α can alter the expression of multiple genes, most 
importantly, glycolytic enzymes such as glucose transporter 1, hexokinase 2, lactate 
dehydrogenase, and monocarboxylate transporter 4 (Hay, 2016). Under normoxic 
conditions, FIH inhibits HIF-1α; it is typically only during hypoxia that FIH is negatively 
regulated to shift cellular metabolism. However, MT1-MMP induces the Warburg Effect 
even under normoxia in cancer cells to increase cell survival (Sakamoto et al., 2011). 
Similarly, the cytoplasmic domain has also been shown to have a role in MCF-7 cell 
survival when grown in serum-starved media (Cepeda et al., 2017b). While small, the 
cytoplasmic domain is involved in MT1-MMP recycling, can be phosphorylated to 
potentially facilitate cell signalling, and influences cellular metabolism via HIF-1α 
activation.  
1.4.4 Proteolysis of intracellular molecules 
Several cell-based proteomic studies have suggested that the MT1-MMP catalytic domain 
is involved in proteolysis of various intracellular substrates. Cleaved molecules include 
enolase-β, enolase-γ, fructose-bisphosphate aldolase A, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), and phosphoglycerate phosphokinase 1 (Cauwe and 
Opdenakker, 2010). Degradation of these metabolic enzymes would stop glucose 
metabolism at the fructose-1,6-bisphosphate (F1,6BP) stage. If stopped there, metabolism 
would shift from oxidative phosphorylation to a different pathway such as glycogenesis, 
again linking MT1-MMP function with metabolic regulation (Hay, 2016). Alternatively, 
F1,6BP can activate Ras, ultimately linking glycolysis and cell proliferation (Peeters et 
al., 2017). Apart from metabolism, MT1-MMP accumulates in the centrosome, where it 
cleaves pericentrin, which coordinates the mitotic spindle (Golubkov et al., 2005), and 
the breast cancer type 2 (BRCA1) susceptibility protein (Wali et al., 2014). Thus, as with 
its well-described extracellular roles, MT1-MMP-mediated proteolysis of intracellular 
proteins also impacts cell growth and survival.  
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1.4.5 MT1-MMP as a transcription factor 
The role of MT1-MMP as a transcription factor is speculative, but related to the fact that 
active MT1-MMP and MMP-2 have been observed to colocalize in the nucleus (Ip et al., 
2007). The functional consequences of this localization are undetermined. However, 
MT1-MMP is trafficked to nuclei in macrophages (Shimizu-Hirota et al., 2012). There it 
putatively modulates the expression of over 100 genes through expression/activation of 
the PI3Kδ/AKT/GSK3β signalling cascades. Many of these genes were linked to immune 
regulation (Shimizu-Hirota et al., 2012). Evidence that MT1-MMP itself is a transcription 
factor is nonexistent as associated changes in expression rely on its ability to facilitate 
signalling cascades and secondary molecules that will eventually function as a 
transcription factor. However, the reported presence of MT1-MMP in the nucleus 
suggests interactions with yet to be identified binding partners.  
1.5 MT1-MMP proteomic research 
Several proteomic approaches have been used to study MT1-MMP protein-protein 
interactions, with focus often on the investigation of proteolytic substrates. Earlier studies 
identified these substrates by observation of degradation products following digestion 
with a soluble MT1-MMP catalytic domain (Ohuchi et al., 1997). However, the use of 
mass spectrometry technology has provided a high-throughput analysis of cellular 
interactomes, especially protein-protein interactions. Although methodology changes 
depending on the approach, protein-protein interaction studies typically use affinity 
purification – mass spectrometry (AP-MS) (Vermeulen et al., 2008). In brief, a “bait” 
protein (MT1-MMP, in this case) is purified from control and treatment samples 
simultaneously with any “prey” proteins bound to it. Following purification, protein 
samples undergo digestion into peptide fragments before mass spectrometry analysis. 
Bottom-up proteomics relies on the resulting MS/MS spectra and bioinformatic tools to 
identify the peptide sequence, and ultimately, the protein. Depending on the need to 
quantify protein abundance between samples, proteins may be labelled for relative 
comparison (Nesvizhskii, 2012). The below six studies have utilized mass spectrometry 
to identify MT1-MMP substrates and binding partner.  
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Unlabelled AP-MS was used to better understand the link between MMPs and 
cardiovascular phenotypes commonly observed in animal models. A total of 15 proteins 
were identified as vascular substrates in human plasma and 12 different proteins in 
human radial arteries (Hwang et al., 2004; Stegemann et al., 2013). Both studies 
identified degradation products by mass spectrometry through comparison of total protein 
following incubation with catalytically active or inactive MT1-MMP. As several protease 
inhibitors are cleaved by MT1-MMP, incubation with MT1-MMP may indirectly activate 
other proteases; thus secondary cleavage products may be misinterpreted as MT1-MMP 
substrates (Hwang et al., 2004). However, advances in technology have created new 
MS-based approaches for the identification of MMP substrates.  
Since mass spectrometry is not inherently quantitative, isotope-coded affinity tagging 
(ICAT) is a MS technique that labels proteins with biotin-tagged reagents that differ in 
isotopic composition analysis (Cauwe and Opdenakker, 2010). Using MDA-MB-231 
breast cancer cells transfected with MT1-MMP, 17 proteins displayed altered abundance. 
Interestingly, only two were typical ECM proteins whereas the others included protease 
inhibitors, chemokines, cytokines, and cell receptors (Tam et al., 2004). Building upon 
this, researchers investigated the proteome-wide effects of prinomastat, a broad-spectrum 
MMP inhibitor. In particular, it was studied how treatment of prinomastat alters MMP-
mediated ECM degradation and membrane protein shedding (Butler et al., 2008). Over 
40 novel substrates were identified within the study, 20 of which were validated 
following incubation with soluble MT1-MMP. Dickkopft-1, pentraxin, thrombospondin, 
cathepsin A/B, and galectin-3-binding protein were observed as novel MT1-MMP 
substrates (Butler et al., 2008). However, intracellular proteins were not considered in 
either of these studies. 
Recent studies of MT1-MMP binding partners utilized similar ICAT techniques for 
protein quantification, but affinity purify FLAG-tagged MT1-MMP and its binding 
partners before mass spectrometry identification. Using this approach, 158 and 163 
proteins were isolated with MT1-MMP in A375 melanoma (Tomari et al., 2009) and 
A431 carcinoma cells (Niiya et al., 2009), respectively. In addition to identifying 
previously known MT1-MMP substrates, non-substrate proteins were also observed and 
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localized to the membrane, cytoplasm, or secretory pathway. This exemplifies the myriad 
of possible partners and their localizations.  
1.6 Objectives and hypothesis 
MT1-MMP has multiple proteolytic and non-proteolytic functions that contribute to 
proper development as well as pathological diseases. The studies described above utilized 
mass spectrometry to identify binding partners of MT1-MMP that contribute to its 
diverse functions. However, previous research used either soluble MT1-MMP domains to 
identify substrates or correlate changes in expression, protein level, or cellular dynamics 
after excessive MT1-MMP transfection; neither of which appear to be physiologically 
relevant. In proteomic studies, the catalytic activity of MT1-MMP is inactivated through 
amino acid substitution (Niiya et al., 2009; Tam et al., 2004; Tomari et al., 2009) or 
exogenous inhibitors (Butler et al., 2008; Stegemann et al., 2013). For this reason, 
studying MT1-MMP binding partners that may act as the source of diverse cellular 
functions is an attractive route to better understand the proteolytic, but more specifically, 
the non-proteolytic contributions of MT1-MMP. The aim of this study was to generate a 
catalog of proteins that associate with MT1-MMP to corroborate previous research 
regarding the role of MT1-MMP in cell migration, invasion, and survival. In a greater 
scope, it is important to understand the basic mechanistic function, particularly with 
respect to binding partners, of relevant proteases within the human degradome.  
I hypothesize that if domains of MT1-MMP have different functions, then 
individual domains will have different binding partners.  
Human MCF-7 breast cancer cells were previously generated to either overexpress 
MT1-MMP (C1) or express a truncated form of MT1-MMP lacking its cytoplasmic 
domain (ΔCD). In this study, these cells were used to: 1) identify MT1-MMP binding 
partners using a combination of co-immunoprecipitation and mass spectrometry, 2) 
compare binding partners between full-length and truncated MT1-MMP expressing cells 
to determine the role of the cytoplasmic domain in MT1-MMP function, and 3) assess 
involvement of the cytoplasmic domain of MT1-MMP in cell signalling pathways to 
better elucidate its role in cell migration.  
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2 MATERIALS AND METHODS 
2.1 Buffers and solutions 
All solutions and buffers are dissolved in ddH2O unless otherwise specified.  
2.1.1 Solutions 
Phosphate Buffered Saline (PBS), pH 7.4: 154 mM NaCl, 1.05 mM KH2PO4, 5.6 mM 
Na2HPO4 
2.1.2 Buffers 
Nonidet P-40 (NP-40) lysis buffer: 100 mM NaCl, 0.1% NP-40, 10% glycerol, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl pH 8.0 
Radioimmunoprecipitation assay (RIPA) lysis buffer: 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl pH 8.0 
SDS running buffer: 25 mM Tris, 192 mM glycine, and 0.1% SDS 
Tris Buffered Saline with Tween 20 (TBST, pH 7.5): 50 mM Tris, 150 mM NaCl, 0.05% 
Tween 20, pH 7.4 
Transfer Buffer: 100 mM Tris, 191 mM glycine, 20% methanol 
Antibody Stripping Buffer: 2 M glycine pH 2.3 
2.2 Cell culture conditions 
The human adenocarcinoma breast cancer cell line MCF-7 (ATCC® HTB-22™) was 
donated by Dr. Postovit, University of Alberta. Cells were incubated at 37ºC with 5% 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM)/ F-12 media supplemented with 
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells 
grown in serum-free conditions were maintained in DMEM/F-12 media containing only 
1% penicillin/streptomycin. Cells were maintained below 80% confluency and passaged 
accordingly using 0.25% Trypsin-EDTA (Gibco).   
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Stable MCF-7 cell lines were previously created as follows by Dr. Mario Cepeda and 
Jake Pelling (Cepeda et al., 2016, 2017b). MCF-7 cells were selected following 
transfection with either full length MT1-MMP or truncated MT1-MMP with its 
cytoplasmic domain removed. Populations were isolated, expanded, and assayed for 
MT1-MMP expression and protein level using qPCR and immunoblotting, respectively. 
Stable transfection of MCF-7 cells with full-length MT1-MMP created a cell line, 
henceforth referred to as C1, with a ~2500-fold increase in expression in comparison to 
MCF-7 parental cells (Cepeda et al., 2016). Transfection with MT1-MMP lacking its 
cytoplasmic domain created a cell line with a ~100-fold increase in MT1-MMP 
expression and produced a protein of lower molecular weight, henceforth referred to as 
ΔCD (Cepeda et al., 2017b).  
2.3 RNA analysis 
2.3.1 RNA extraction and real-time PCR 
Real-time PCR (qPCR) analysis was performed to determine mRNA transcript levels 
between parental MCF-7, C1, and ΔCD cells. RNA was collected 24 hours after cells 
were seeded at a density of 5 x 105 cells/mL using the RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instructions. RNA concentration and quality were 
determined using a NanoDrop2000 spectrophotometer (Thermo Fisher Scientific). cDNA 
was synthesized from 1 μg RNA using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems) according to manufacturer’s instructions. Glyceraldehyde       
3-phosphate dehydrogenase (GAPDH) expression was used as an internal control 
(Cepeda et al., 2016). cDNA was amplified using primers (sequences provided in Table 
1) as well as quantified using SensiFAST SYBR (Bioline) and a CFX96 Real-Time PCR 
Detection System (BioRad). qPCR was conducted at 95ºC for 2 minutes, followed by a 
repeated reaction schedule of denaturation at 95ºC for 5 seconds, primer annealing at 
60ºC for 10 seconds, and primer extensions at 72ºC for 20 seconds. Transcript levels 
were calculated and normalized to the internal control. Gene expression relative to 
parental MCF-7 cell transcript was calculated using the ΔΔCt method (Livak and 
Schmittgen, 2001).  
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Table 1. Primer sequences used for qPCR. 
Gene Forward (5’ → 3’) Reverse (5’ → 3’) 
BSG GGCTGTGAAGTCGTCAGAACAC ACCTGCTCTCGGAGCCGTTCA 
BST2 GCATGTGCTGCCTGTTGTTAT TCAGGTGTGCTCTCCCTCAA 
CDC42 TAACTCACCACTGTCCAAAGACTC CCTCATCAAACACATTCTTCAGACC 
CDH1 GCCGCTGGCGTCTGTAGGAA TGACCACCGCTCTCCTCCGA 
CDKN1A GGGCTGGGAGTAGTTGTCTT ACAGGAGCTGGAAGGTGTTT 
EHF GCACAACGGCACAACCTTC TGACTTGTGGAACCCAACGG 
GAPDH ACCCACTCCTCCACCTTTGA CTGTTGCTGTAGCCAAATTCGT 
ITGB1 GAAGGGTTGCCCTCCAGA GCTTGAGCTTCTCTGCTGTT 
MMP14 GCAGAAGTTTTACGGCTTGCA TCGAACATTGGCCTTGATCTC 
SLC39A1 GCCTACCCCCAGCGTTATTT ACAGGTCCCAAAACAGGTCA 
SMAD2 TGCACACATCTACACTGGCT TGAGGGGTGGGGATGGTATT 
SMAD4 GTAGAGGCCAGCTTTGTGGT AATCAATCCAAGCCCGTGAGT 
SNAI1 AGGGACTGTGAGTAATGGCTG AGTTCTGGGAGACACATCGG 
TGFB1 TTATTGAGCACCTTGGGCACT TGGGCTTGTTTCCTCACCTTT 
TGFB2 CTATGTTCTGCCAACGCCAG AACCAACCCCAGAAAGCACG 
TGFB3 AGACCCTGTGTTCATTTGGTGT TACCTCAGTCTATGCGTCTGG 
TGFBR1 TCTGTTGCCTTTGGGTCAGC AATCAAGGGTTTGGGGACCA 
TGFBR2 TGTGGGTGGGCTGAGAGTTA AGAGGTCAATGGGCAACAGC 
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  (Table 1 continued) 
Gene Forward (5’ → 3’) Reverse (5’ → 3’) 
TGFBR3 CGCGTGCCAGTCTTTTTGTA TCACATAGGACTCACCCAACA 
TP53INP1 TATAGGGGCAGGGCATGAGT CGAGAAACACATTAAGAAGGCACA 
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2.4 Protein analysis 
2.4.1 Protein collection and immunoblotting 
Immunoblotting was performed to assay for changes in protein level between cell lines. 
Cells were seeded at a density of 5 x 105 cells/mL. Twenty-four hours later, cells were 
washed with PBS and disrupted using RIPA lysis buffer supplemented with 
phosphatase/protease inhibitor cocktail (Thermo Scientific). Collected protein lysates 
were shaken on ice for 20 minutes and sonicated three times for 10 seconds each. Protein 
concentration was quantified using a Pierce bicinchoninic acid (BCA) Protein Assay Kit 
(Thermo Scientific). Either 10 or 20 μg of protein per sample was mixed with the 
appropriate amount of Laemmli sample buffer (BioRad) and subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS PAGE) at 130 V for approximately three 
hours in SDS running buffer. Protein was transferred to a polyvinylidene difluoride 
(PVDF) membrane (BioRad) overnight at 4ºC using 12 V. Membranes were then blocked 
in either 0.5% or 5% bovine serum albumin (BSA) (Fischer Scientific) dissolved in 
TBST for 30 minutes at room temperature. Blots were subsequently incubated overnight 
at 4ºC with a primary antibody (section 2.4.3) followed by an appropriate secondary 
antibody for one hour at room temperature. Blots were analyzed using a ChemiDoc™ 
Imaging System (BioRad) and quantified using Image Lab (BioRad) software. 
2.4.2 Immunoblot densitometry analysis 
Chemiluminescence was analyzed using a ChemiDoc™ Imaging System (BioRad) and 
Image Lab software (BioRad). Band intensity of a protein of interest was quantified and 
normalized to β-actin using three independent biological samples (Cepeda et al., 2016). 
TGF-β1 SLC protein level was shown as a ratio of TGF-β1 SLC signal standardized to 
β-actin before comparison to parental MCF-7. SMAD2 activation is presented as a ratio 
between the phospho-SMAD2 and total SMAD2 band intensities within each sample 
normalized to parental MCF-7 cells.  
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2.4.3 Antibodies  
The following antibodies were used: mouse anti-MT1-MMP (1:200, sc-377097, Santa 
Cruz), rabbit anti-MT1-MMP (1:1000, AB6004, Millipore), rabbit anti-MT1-MMP 
(1:2000, ab51074, Abcam), rabbit anti-TGF-β1 (1:2000, ab92486, Abcam), rabbit anti-
hyaluronan-mediated motility receptor (HMMR) (1:200, ab124729, Abcam), mouse anti-
vitronectin (1:250, ab13413, Abcam), rabbit anti-fragile X mental retardation 1 (FMR1) 
(1:200, ab17722, Abcam), rabbit anti-phosho-SMAD2 (1:1000, 138D4, Cell Signaling 
Technology), mouse anti-SMAD2 (1:1000, 610843, BD Transduction Laboratories), 
mouse anti-β-actin (1:1000, sc-47778, Santa Cruz), and normal rabbit immunoglobulin G 
(IgG) control (AB-105-C, R&D Systems). Following primary antibody incubation, goat 
anti-mouse IgG (H+L) (BioRad) and goat anti-rabbit IgG (H+L) (Invitrogen) horseradish 
peroxidase (HRP) conjugates were used as secondary antibodies for immunoblot analysis 
(1:10 000). Clarity™ Western Enhanced Chemiluminescence Substrate (BioRad) was 
used according to manufacturer’s instructions to detect secondary antibody.   
The MT1-MMP antibody (ab51074) used for immunoprecipitation recognizes the 
extracellular region of MT1-MMP. Thus, MT1-MMP lacking its cytoplasmic domain was 
efficiently isolated.  
2.4.4 Immunoprecipitation 
Immunoprecipitation was used to isolate MT1-MMP and its binding partners in MCF-7, 
C1, and ΔCD cell lines. Cells were seeded at a density of 4 x 105 cells/mL in a 60 mm 
cell culture dish and incubated for twenty-four hours. On ice, cells were washed with cold 
PBS before lysate was collected using NP-40 lysis buffer supplemented with 
phosphatase/protease inhibitor cocktail (Thermo Scientific). Protein lysate was shaken on 
ice for 20 minutes, homogenized using a 20G syringe, and quantified using a Pierce BCA 
Protein Assay Kit (Thermo Scientific). Aliquots containing 100 μg of protein were 
incubated with rabbit anti-MT1-MMP (ab51074) at 25:1 v/v ([ab51074] is 0.174 mg/ml). 
In parallel, aliquots of 100 μg of protein were incubated with the same volume of rabbit 
IgG antibody as a negative control. SureBeads Protein A Magnetic Beads (BioRad) were 
used according to manufacturer’s instructions to precipitate the antibody complexes. 
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Following immunoprecipitation, proteins were eluted from beads with either Laemmli 
sample buffer for immunoblotting analysis of MT1-MMP and its binding partners, or 
200 mM glycine (pH 2.0) for in-solution digestion and subsequent mass spectrometry 
analysis. To prevent detection of heavy and light IgG chains of the primary antibody used 
to immunoprecipitate MT1-MMP, rabbit anti-MT1-MMP was used to immunoprecipitate 
whereas mouse anti-MT1-MMP was used in immunoblot analysis.  
2.4.5 In-solution trypsin digestion 
Following immunoprecipitation of MT1-MMP from protein lysate, co-
immunoprecipitation eluent underwent in-solution digestion before mass spectrometry 
analysis. Beads used to precipitate MT1-MMP protein complexes were incubated with 
200 mM glycine (pH 2.0) for fifteen minutes in a thermoshaker at 56ºC and 400 rpm 
before neutralization with Tris-HCl (pH 8.0). Samples were reduced with 10 mM 
dithiothreitol (DTT; dissolved in 100 mM NH4HCO3) for one hour at room temperature. 
Following reduction, samples were alkylated using 100 mM iodoacetamide (dissolved in 
100 mM NH4HCO3) for one hour at room temperature in the dark. Protein was 
precipitated with trichloroacetic acid (TCA) extraction, resuspended in 50 mM NH4HCO3 
(pH 7.8), and quantified using a spectrophotometer (NanoDrop 2000, Thermo Scientific) 
and protein standards. Samples were then subjected to in-solution digestion with 2% 
(w/w) sequencing-grade trypsin (Thermo Scientific; resuspended in 50 mM NH4HCO3) 
for 18 hours at 37ºC and 700 rpm. Additionally, 1% (w/w) trypsin was added for 4 hours 
at 37ºC and 1400 rpm. Resulting peptide samples were purified and concentrated using 
C18 Spin Columns (Thermo Scientific) according to manufacturer’s instructions. Peptide 
samples were quantified, lyophilized, and resuspended in 0.1% formic acid before 
analysis by liquid chromatography-tandem mass spectrometry.  
2.4.6 Liquid chromatography-tandem mass spectrometry 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of 3 biological 
replicates from each cell line were carried out at the Don Rix Protein Identification 
Facility, Department of Biochemistry (UWO). Every mass spectrometry run included 
samples immunoprecipitated with an MT1-MMP antibody, identical samples 
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immunoprecipitated with a rabbit IgG antibody (negative control), as well as a BSA 
solution that underwent in-solution digestion (positive control). Samples were separated 
using an ACQUITY UPLC M-Class system (Waters Corporation) connected to an 
Orbitrap Elite Mass Spectrometer (Thermo Fisher Scientific). Buffer A consisted of 
water/0.1% formic acid and buffer B consisted of acetonitrile/0.1% formic acid. Samples 
were trapped for 6 minutes at a flow rate of 5 μL/min using 99% buffer A and 1% buffer 
B on an ACQUITY UPLC M-Class Symmetry C18 Trapping Column (100 Å, 5 μm, 
180 μm x 20 mm, Waters). After trapping, peptides were separated using an ACQUITY 
UPLC M-Class Peptide BEH C18 Column (130 Å, 1.7 μm, 75 μm x 250 mm) operating 
at a flow rate of 300 nL/min at 35°C using a 5-40% acetonitrile gradient over 90 minutes. 
An Orbitrap Elite Mass Spectrometer recorded the mass-to-charge ratio (m/z) of ions over 
the range of 380-1600. The mass spectrometer was controlled by Xcalibur™ software 
(Thermo Fisher Scientific) and operated in the data-dependent mode using FT/IT/CID 
Top 10 scheme.  
2.4.7 Protein Identification 
Data analysis was performed using PEAKS Studio 10.0 (Bioinformatics Solutions Inc.). 
MS/MS spectra were searched against the Human Uniprot database with trypsin 
specificity (updated January 2019 with 20 380 entries; UniProt Consortium, 2019). 
Missed cleavages were set to 3. Cysteine carbamidomethylation was set as a fixed 
modification, whereas oxidation (M) and deamidation (NQ) were set as variable 
modifications (max number of modifications per peptide = 5). All other PEAKS Studio 
software settings were left as default. Peptide and protein false discovery rate (FDR) was 
set to 1% (Hughes et al., 2012). FDR values were calculated using the Decoy-Fusion 
method in PEAKS. Proteins identified by a minimum of one unique peptide and isolated 
in ≥ 2 biological replicates were retained for downstream analysis (Kuljanin et al., 2017), 
unless otherwise specified. Proteins identified following rabbit IgG pulldown were 
considered non-specific background proteins and subsequently removed from the MT1-
MMP co-immunoprecipitation datasets. Additionally, structural components of the 
ribosome and spliceosome were removed. Immunoprecipitation followed by immunoblot 
analysis was used to confirm selected complexes detected by LC-MS/MS as described in 
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sections 2.4.1 and 2.4.2. Antibodies specific to hyaluronan mediated motility receptor 
(HMMR), fragile X mental retardation 1 (FMR1), and vitronectin (VTN) were used to 
validate mass spectrometry results.  
Following PEAKS analysis, the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING) was used to create protein-protein interaction (PPI) networks. 
STRING (version 11.0) is a well-known public database of protein associations that 
covers 19 566 protein coding genes from Homo sapiens (NCBI taxon ID: 9606) 
(Szklarczyk et al., 2019). Proteins identified by mass spectrometry were mapped via 
STRING using co-expression analysis, pathway knowledge from curated databases, and 
experimentally validated associations (confidence = 0.4). Cytoscape software 
(version 3.7) was used to construct a PPI network. Within a PPI network, Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to identify 
enrichment of pathway-specific genes within the network. KEGG is a manually curated 
database resource with a collection of pathway maps integrating many aspects of the 
biological system (genes, proteins, RNAs, etc.).  
2.5 Statistics 
Statistical analysis and graphing of qPCR and immunoblot data was performed using 
Microsoft Excel (Office 365). Data is present as mean ± SEM. Means were compared 
using one-way ANOVA followed by Tukey’s post-hoc test. Levels of statistical 
significance are as follows: ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05. 
KEGG pathway analysis enrichment scores are presented as FDR. 
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3 RESULTS 
In this study, MCF-7 cell lines were used to: 1) identify MT1-MMP binding partners, 2) 
compare binding partners isolated from full-length and truncated MT1-MMP expressing 
cells, and 3) assess the involvement of the MT1-MMP cytoplasmic domain in cell 
signalling. Objectives 1 and 2 identified MT1-MMP binding partners that alluded to the 
role of the cytoplasmic domain on MT1-MMP function. In parallel with proteomic 
experiments, a different approach was used in Objective 3 to identify changes in 
expression and protein level between the cell lines. This was done to corroborate previous 
research that observed an increase in ΔCD, but not C1, cell migration relative to parental 
MCF-7 cells (Cepeda et al., 2016, 2017b). 
3.1 Stable MCF-7 cell lines, C1 and ΔCD, have altered expression of 
MT1-MMP 
Cell lines used were repeatedly tested via qPCR and immunoblotting to ensure consistent 
levels of MT1-MMP over the course of this study. MCF-7 cells were previously 
transfected with either full length MT1-MMP (Cepeda et al., 2016) or MT1-MMP 
lacking its cytoplasmic domain (Cepeda et al., 2017b). Parental MCF-7 cells have low 
abundance of MT1-MMP transcript and did not show any detectable levels of MT1-MMP 
protein (Figure 4). C1 cells created to have a ~2500-fold increase (p<0.0001) in 
MT1-MMP produced a 63 kDa band as expected (Figure 4). The ΔCD cell lines, which 
expresses ~100-fold increase (p<0.001) of MT1-MMP lacking its cytoplasmic domain 
produced a corresponding smaller (59 kDa) band as expected (Figure 4). 
3.2 Immunoprecipitation of MCF-7, C1, and ΔCD cell line lysates with anti-
MT1-MMP antibody isolated 248 unique proteins  
To identify MT1-MMP binding partners, protein lysate from each cell line was 
immunoprecipitated with an MT1-MMP antibody. The resulting precipitated complexes 
were subsequently analyzed with mass spectrometry. As a negative control, cell lysates 
were immunoprecipitated with a normal rabbit IgG antibody to identify any non-specific 
antibody interactions. Due to the nature of ultra-sensitive mass spectrometry, these non-
specific proteins were removed. Additionally, components of the ribosome were also  
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Figure 4. Stable transfection of MCF-7 cell lines produce different MT1-MMP 
expression profiles. 
(a) Average expression level of MT1-MMP from qPCR analysis of parental MCF-7, C1, 
and ΔCD cell lines. Relative to parental MCF-7 cell expression, C1 MT1-MMP 
expression is increased 2529-fold (p≤0.0001) whereas ΔCD is increased 83-fold 
(p≤0.001). Log2 transformed mean fold change ± SEM is presented and was compared 
using one-way ANOVA and Tukey’s post-hoc test; ****, p ≤ 0.0001; ***, p ≤ 0.001 
(n=4). (b) Immunoblot analysis of parental MCF-7, C1, and ΔCD cell lysate show 
different levels of MT1-MMP protein level. MT1-MMP protein cannot be visualized by 
immunoblotting in MCF-7 cells, however, stable transfection of full-length MT1-MMP in 
C1 cells showed a band corresponding to MT1-MMP (63 kDa). ΔCD MT1-MMP 
transfection results in an increase of MT1-MMP protein, but at a lower molecular weight 
due to the truncated protein (59 kDa). β-actin was used as a loading control.  
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removed due to their overabundance in the rabbit IgG pulldown. Next, a protein was 
considered a valid binding partner if it was identified by a minimum of one unique 
peptide and observed in ≥ 2 biological replicates. Prior to filtering and removal of non-
specific proteins, 939 proteins were identified in MCF-7 cells, 919 proteins in C1 cells, 
and 1051 proteins in ΔCD cells following immunoprecipitation with an MT1-MMP 
antibody (Figure 5a). Following removal of non-specific proteins that were pulled down 
with the MT1-MMP antibody as well as the rabbit IgG antibody, the catalog of MT1-
MMP binding partners was subjected to KEGG analysis.  
KEGG analysis identified an enrichment of proteins associated with various pathways. 
Sorted by FDR, the top 10 enriched pathways and their identified proteins are listed 
(Appendix A). The pathways include: spliceosome (hsa03040), RNA transport 
(hsa03013), RNA degradation (hsa03018), mRNA surveillance pathway (hsa03015), 
protein processing in the endoplasmic reticulum (hsa04141), pathogenic Escherichia coli 
infection (hsa05130), Huntington’s disease (hsa05016), endocrine and other factor-
regulated calcium reabsorption (hsa04961), non-homologous end-joining (hsa03450), 
hepatocellular carcinoma (hsa05225), and endocytosis (hsa04144) (Appendix A). 
Similarly, KEGG analysis of proteins pulled down with the control anti-rabbit IgG 
identified enrichment in various pathways including the spliceosome (11 of 130 genes, 
FDR=0.0145; data not shown). Due to the nature of spliceosomal-related proteins having 
a unique, sometimes solely known function, these proteins were considered background 
proteins. Therefore, 19 protein were removed from the pool of binding partners.  
Following the removal of all non-specific proteins, the final dataset contained 200 
proteins isolated in MCF-7 cells, 168 proteins isolated in C1 cells, and 70 proteins 
isolated in ΔCD cells; a reduction of 79%, 82%, and 93%, respectively, from the original 
dataset (Figure 5a). When proteins isolated in each cell line were compared, a total of 248 
unique proteins immunoprecipitated with MT1-MMP in MCF-7, C1, and ΔCD cells 
(Figure 5b, Appendix B). STRING analysis of the 248 proteins generated a protein-
protein interaction network of 224 nodes (proteins) and 1116 edges (protein-protein 
interactions; data not shown). Subsequent KEGG pathway analysis of the catalog
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Figure 5. Total number of proteins immunoprecipitated with MT1-MMP in 
parental MCF-7, C1, and ΔCD cell lines.  
(a) A total of 939 proteins were identified in parental MCF-7 cells, 919 proteins in C1 
cells, and 1051 proteins in ΔCD cells following immunoprecipitation with an MT1-MMP 
antibody. Following removal of non-specific proteins, 200 proteins were identified as 
true MT1-MMP interactions in parental MCF-7 cells, 168 protein in C1 cells, and 70 
proteins in ΔCD cells. (b) Upon comparison of proteins isolated in each cell line, a total 
of 248 unique proteins immunoprecipitated with MT1-MMP. A complete list of proteins 
can be found in Appendix B. 
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of 248 proteins identified enrichment in pathways including: RNA transport, RNA 
degradation, mRNA surveillance pathway, protein processing in the endoplasmic 
reticulum, Huntington’s disease, endocrine and other factor-regulated calcium 
reabsorption, adrenergic signaling in cardiomyocytes (hsa04261), non-homologous end-
joining, hepatocellular carcinoma, and endocytosis (Table 2). 
3.3 Select MT1-MMP binding partners identified by mass spectrometry are 
validated with immunoblotting 
Select proteins identified by mass spectrometry were validated with immunoblotting 
following immunoprecipitation with an MT1-MMP antibody. Elution of proteins from 
magnetic beads with Laemmli buffer also elutes the immobilized antibody bound to the 
beads. As a result, Western blot bands corresponding to the antibody heavy (50 kDa) and 
light (25 kDa) polypeptide chains appear regardless of primary antibody species due to 
cross-reactivity. For this reason, mass spectrometry identified proteins that were chosen 
to be validated had a molecular weight greater than 60 kDa to be accurately visualized. 
The proteins selected include hyaluronan mediated motility receptor (HMMR), fragile X 
mental retardation 1 (FMR1), and vitronectin (VTN). As expected, proteins bands 
corresponding to MT1-MMP were observed in MCF-7 and C1 cell lysate following anti-
MT1-MMP immunoprecipitation (Figure 6). Due to oversaturation of the immunoglobin 
heavy chain chemiluminescent signal (50 kDa), membranes were trimmed at ~60 kDa. 
As a result, MT1-MMP was poorly visualized in ΔCD cell lysate due to its lower 
molecular weight (59 kDa). In agreement with HMMR and FMR1 being identified as 
putative MT1-MMP binding partners by mass spectrometry, bands corresponding to 
HMMR (84 kDa) and FMR1 (80 kDa) were observed in all cell lysates following anti-
MT1-MMP immunoprecipitation, but not rabbit IgG pulldown. While vitronectin was 
identified by mass spectrometry as a putative binding partner MCF-7 and C1 cells, VTN 
(62 kDa) was only identified in MCF-7 cell lysate following anti-MT1-MMP 
immunoprecipitation.  
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Table 2. Top 10 most significantly enriched KEGG pathways represented by 248 proteins co-immunoprecipitated with 
MT1-MMP from MCF-7, C1, and ΔCD cell linesa. 
ID: KEGG Pathway Countb Sizeb Genes FDRa 
RNA transport (hsa03013) 18 159 CASC3 EIF2S1 EIF2S3 EIF3C EIF3CL 1.61 x 10-9 
EIF3I EIF4A1 EIF4G1 FMR1 FXR1 
FXR2 NUP210 PABPC1 PABPC4 PNN 
RAN SEC13 UPF1   
RNA degradation 
(hsa03018) 
11 77 CNOT1 CNOT2 CNOT3 CNOT7 DDX6 1.1 x 10-6 
EDC4 HSPA9 HSPD1 PABPC1 PABPC4 
XRN2     
mRNA surveillance 
pathway (hsa03015)  
11 89 CASC3 CPSF1 CPSF2 FIP1L1 PABPC1 2.85 x 10-6 
PABPC4 PNN PPP1CA PPP1CC UPF1 
WDR33     
Protein processing in the 
endoplasmic reticulum 
(hsa04141)  
12 161 BAG2 DNAJA1 DNAJA2 EIF2S1 HSP90AA1 8.25 x 10-5 
HSP90AB1 HSPA1A HSPA5 RPN1 RRBP1 
SEC13 SSR1    
Pathogenic Escherichia coli 
infection (hsa05130)  
7 53 CTNNB1 NCL TUBB2A TUBB2B TUBB6 0.00033 
YWHAQ YWHAZ    
Huntington’s disease 
(hsa05016)  
10 193 AP2A1 AP2B1 AP2M1 ATP50 ATP5A1 0.0071 
ATP5C1 CLTC DCTN1 NDUFA4 SLC25A5 
Endocrine and other factor-
regulated calcium 
reabsorption (hsa04961)  
5 47 AP2A1 AP2B1 AP2M1 ATP1A1 CLTC 0.0118 
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(Table 2 continued)    
ID: KEGG Pathway Count Size Genes FDR 
Adrenergic signaling in 
cardiomyocytes (hsa04261)  
8 139 ATP1A1 ATP2A2 CALM1 GNAI3 PPP1CA 0.0118 
PPP1CC TPM1 TPM3   
Non-homologous end-
joining (hsa03450)  
3 13 PRKDC XRCC5 XRCC6   0.0187 
Hepatocellular carcinoma 
(hsa05225)  
8 163 ACTL6A ARID2 CTNNB1 KEAP1 PBRM1 0.0229 
SMARCA4 SMARCC2 SMARCE1   
Endocytosis (hsa04144)  10 242 AP2A1 AP2B1 AP2M1 ARF5 CAPZA 0.0229 
CAPZB CLTC HSPA1A RAB10 TFRC 
 
a Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate 
b Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway 
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 Figure 6. Validation of putative MT1-MMP binding partners HMMR, FMR1, and 
VTN.   
Lysates from parental MCF-7, C1, and ΔCD cell line were collected, immunoprecipitated 
with an MT1-MMP antibody, and immunoblotted to confirm pulldown of proteins 
identified by mass spectrometry. Hyaluronan mediated motility receptor (HMMR), 
fragile X mental retardation 1 (FMR1), and vitronectin (VTN) were identified by mass 
spectrometry to co-immunoprecipitate with MT1-MMP. HMMR and FMR1 were 
identified in MCF-7, C1, and ΔCD cells whereas VTN was found in MCF-7 and C1 
(Appendix B). In parallel, samples were immunoprecipitated with either a rabbit 
MT1-MMP (IP:MT1-MMP) or normal rabbit IgG (IP: IgG) antibody followed by 
Western blot analysis. Bands corresponding to HMMR (84 kDa) and FMR1 (80 kDa) 
were observed in all cell lines. MT1-MMP (63 kDa) protein was visualized in MCF-7 
and C1 lysate. Since membranes are trimmed at 60 kDa to limit oversaturation of the 
heavy chain IgG chemiluminescent signal, the truncated form (59 kDa) of MT1-MMP 
could not be visualized in ΔCD cell lysate. VTN (62 kDa) was observed only in MCF-7 
cells. Pulldown with a rabbit IgG antibody showed no bands corresponding to HMMR, 
FMR1, MT1-MMP, or VTN protein when probed with their respective antibodies.  
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3.4 Proteins immunoprecipitated from full-length MT1-MMP expressing cell 
lines, but not ΔCD, are involved in various KEGG pathways 
Towards identifying any functional consequences of MT1-MMP lacking its cytoplasmic 
domain, KEGG analysis was used to compare proteins isolated solely in cells expressing 
full-length MT1-MMP (MCF-7 and C1) with those isolated in ΔCD. The premise of this 
comparison was to identify potential cytoplasmic binding partners that may be important 
for cell signalling or MT1-MMP localization that would be absent in ΔCD. A total of 177 
proteins were identified following immunoprecipitation of MT1-MMP in MCF-7, C1, or 
both cell lines in comparison to 71 proteins identified in ΔCD (Figure 5b). KEGG 
analysis of proteins isolated in MCF-7 and C1 identified enrichment in various pathways 
(Table 3) such as: protein processing in the ER, RNA degradation, mRNA surveillance, 
RNA transport, pathogenic E. coli infection, non-homologous end-joining, protein export 
(hsa03060), Huntington’s disease, adrenergic signaling in cardiomyocytes, and 
endocytosis. Except for protein export, these pathways were enriched following KEGG 
analysis of the original 248 proteins isolated with MT1-MMP pulldown (Table 2). 
Conversely, KEGG analysis of proteins isolated from ΔCD identified an enrichment of 
proteins related to RNA transport (7 of 159 genes; FDR=1.3 x 10-4; data not shown). 
Therefore, enrichment identified in the 248-protein dataset is dependent on the proteins 
isolated from full-length MT1-MMP expressing cells, and not ΔCD. Marked proteins (*) 
within the table will be discussed later (section 4.4).  
3.5 ΔCD cells have reduced TGF-β1 expression, but not small latency 
complex protein level 
A fundamental embryonic process that can be modulated by MT1-MMP activity is the 
epithelial-mesenchymal transition. An objective of this research was to assess the 
involvement of the MT1-MMP cytoplasmic domain in cell signalling pathways to better 
elucidate its role in cell migration. To determine if expression of genes involved in EMT 
differed between the cell lines, total RNA was extracted from each cell line to compare 
transcript levels. Many of the EMT-associated genes chosen, Snail (SNAI1), cell division 
cycle 42 (CDC42), cadherin 1 (CDH1), integrin subunit β 1 (ITGB1), and extracellular 
matrix metalloproteinase inducer (BSG), did not differ between parental MCF-7 cells and
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Table 3. Top 10 most significantly enriched KEGG pathways represented by 177 proteins co-immunoprecipitated solely with 
full-length MT1-MMP expressing cells – MCF-7 and C1a.  
ID: KEGG Pathway Countb Sizeb Genes FDRa 
Protein processing in the 
endoplasmic reticulum 
(hsa04141)  
11 161 BAG2 DNAJA1 DNAJA2 EIF2S1 HSP90AA1 3.61 x 10-5 
HSP90AB1 HSPA5 RPN1* RRBP1 SEC13* 
SSR1*     
RNA degradation (has03018)  8 77 CNOT1 CNOT2 CNOT3 CNOT7 EDC4 3.61 x 10-5 
HSPA9 HSPD1 XRN2   
mRNA surveillance pathway 
(has03015)  
9 89 CASC3 CPSF1 CPSF2 FIP1L1 PNN 3.61 x 10-5 
PPP1CA PPP1CC UPF1 WDR33  
RNA transport (has03013)  11 159 CASC3 EIF2S1 EIF2S3 EIF3C EIF3CL 3.61 x 10-5 
EIF4A1 NUP210 PNN RAN SEC13 
UPF1     
Pathogenic Escherichia coli 
infection (has05130)  
6 53 CTNNB1 NCL TUBB2A TUBB2B TUBB6 0.00045 
YWHAZ     
Endocrine and other factor-
regulated calcium reabsorption 
(has04961)  
5 47 AP2A1 AP2B1 AP2M1 ATP1A1 CLTC 0.0026 
Non-homologous end-joining 
(has03450)  
3 13 PRKDC XRCC5 XRCC6   0.0083 
Protein export (has03060)  3 23 HSPA5 SRP14* SRP72*   0.0314 
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(Table 3 continued) 
ID: KEGG Pathway Count Size Genes FDR 
Huntington’s disease 
(has05016)  
7 193 AP2A1 AP2B1 AP2M1 ATP50 CLTC 0.0326 
DCTN1 NDUFA4    
Adrenergic signaling in 
cardiomyocytes (has04261)  
6 139 ATP1A1 ATP2A2 GNAI3 PPP1CA PPP1CC 0.0326 
TPM1     
Endocytosis (has04144)  8 242 AP2A1* AP2B1* AP2M1 ARF5 CAPZB 0.0326 
CLTC* RAB10* TFRC   
 
a Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate 
b Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway 
* proteins are discussed in Chapter 4  
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C1 or ΔCD (Figure 7a). However, a 5-fold reduction of TGFB1 expression was observed 
in the ΔCD line (p≤0.05), but not in the C1 cell line. Immunoblot analysis determined 
that the reduction of TGFB1 expression in ΔCD cells did not result in a decrease in 
TGF-β1 protein. Bands corresponding to TGF-β1 small latency complex (44 kDa) were 
quantified with no significant difference observed between cell lines (Figure 7b). 
Quantification of secreted TGF-β1 in media using protein precipitation and 
immunoblotting was unsuccessful.  
3.6 ΔCD cells have altered expression of TGFβ subfamily members and 
increased SMAD2 phosphorylation 
To better understand the decrease of TGFB1 RNA levels in ΔCD cells, the expression of 
other TGF-β family members was quantified. In contrast to a decrease of TGFB1 
expression, ΔCD cells had increased levels of TGFB2, TGFB3, and TGFBR3 (p<0.05) in 
comparison to parental MCF-7 cells (Figure 8a). No change in expression of TGF-β 
isoforms or receptors was observed in C1 cells relative to parental MCF-7 cells. Since 
TGF-β1 and TGF-β2 share similar activation mechanisms of TGF-β signalling through 
the canonical SMAD pathway, levels of SMAD2 phosphorylation was quantified. Protein 
bands corresponding to phospho-SMAD2 (60 kDa) were quantified relative to total 
SMAD2 levels (58 kDa). ΔCD cells displayed a 3.5-fold increase in SMAD2 
phosphorylation relative to parental MCF-7 cells, with no change observed in C1 cells 
(Figure 8b). Additionally, SMAD2 as well as its cofactor SMAD4 had increased transcript 
levels solely in ΔCD cells (p<0.05) (Figure 8c).  
To corroborate the observation of increased SMAD2 phosphorylation in ΔCD cells, the 
expression of genes known to be regulated through canonical TGF-β signalling were 
quantified. Solute carrier family 39 member 1 (SLC39A1) (Özdemir et al., 2014), cyclin 
dependent kinase inhibitor 1A (CDKN1A) (Liu et al., 2010), ETS homologous factor 
(EHF) (Yamazaki et al., 2015), bone marrow stromal cell antigen 2 (BST2) (Sayeed et al., 
2013), and tumour protein P53 inducible nuclear protein 1 (TP53INP1) (Liu et al., 2015) 
are select genes known to be either upregulated or downregulated in response to TGF-β 
treatment. Thus, corresponding changes in their RNA levels were used to confirm 
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Figure 7. Cells with MT1-MMP lacking its cytoplasmic domain have an altered 
profile of TGF-β1 levels. 
 (a) qPCR analysis of parental MCF-7, C1, and ΔCD cell lines revealed similar 
expression of genes associated with epithelial-mesenchymal transition. No statistically 
significant changes were observed in SNAI1, CDC42, CDH1, ITGB1, or BSG levels. 
However, ΔCD cells had a significant decrease in TGFB1 expression relative to parental 
MCF-7 cells (p≤0.05). The results of four biological replicates are shown as log2 
transformed mean fold-change ± SEM and were compared using one-way ANOVA and 
Tukey’s post-hoc test; *, p ≤ 0.05. (b) Representative immunoblot image (left) of 
intracellular TGF-β1 protein level in parental MCF-7, C1, and ΔCD cells. Western blot 
analysis was used to determine if a reduction of TGFB1 expression as seen via qPCR 
resulted in altered TGF-β1 protein levels. No change of intracellular TGF-β1 (44 kDa) 
sequestered in its small latency complex (SLC) was observed between cell lines 
following densitometry quantification (right). Band intensities were normalized to β-actin 
before comparison to parental MCF-7 cells. Means from three biological replicates are 
presented as mean arbitrary units (a.u.) ± SEM and were analyzed using one-way 
ANOVA.  
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Figure 8. Deletion of the cytoplasmic domain of MT1-MMP increased canonical 
SMAD2-dependent TGF-β signalling.  
(a) Expression of different TGF-β isoforms and receptors was assessed using qPCR 
analysis. TGFB1 decreased in ΔCD, however, expression of TGFB2, TGFB3, and 
TGFBR3 increased relative to parental MCF-7 cells (p ≤ 0.05). No change was observed 
in C1 cells relative to parental MCF-7 cells. The results of three biological replicates are 
shown as log2 transformed mean fold-change ± SEM and were compared using one-way 
ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05. (b) Representative immunoblot image 
(left) of phospho-SMAD2 (60 kDa) and total SMAD2 (58 kDa) protein levels in parental 
MCF-7, C1, and ΔCD cells. An increase in the relative level of SMAD2 phosphorylation 
was observed solely in ΔCD cells. Densitometry quantification (right) of three biological 
replicates are shown, with phospho-SMAD2 normalized to total SMAD2 for each sample 
before comparison to parental MCF-7. Means are presented as arbitrary units (a.u.) ± 
SEM and were analyzed using one-way ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05. 
(c) qPCR analysis of SMAD2 and SMAD4 in all cell lines. ΔCD cells have significantly 
higher expression of SMAD2 and SMAD4 (p ≤ 0.05) relative to parental MCF-7 cells. 
Log2 transformed mean fold-change ± SEM from three biological replicates were 
compared using one-way ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05; ***, p ≤ 0.001.  
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downstream effects of the different TGF-β/SMAD2 levels observed between the cell 
lines.  
As ΔCD cells increased phospho-SMAD2 levels, genes that have been shown to be 
upregulated through TGF-β signalling – SLC39A1, CDKN1A, and EHF – should have 
elevated RNA levels in ΔCD cells. Indeed, SLC39A1 expression increased 1.5-fold 
(p<0.01) in ΔCD cells, but not C1 (Figure 9). In contrast, EHF expression was 6.2-fold 
higher (p<0.01) in C1 cells relative to parental MCF-7 cells. CDKN1A (aka P21) did not 
change its expression levels in any cell line. Conversely, previous research has linked 
TGF-β signalling with the downregulation of BST2 and TP53INP1. Accordingly, a 
decrease in expression was expected in ΔCD cells. BST2 levels decreased 3.1-fold 
(p<0.001) in C1 and 16.4-fold (p<0.0001) in ΔCD cells. No change in TP53INP1 RNA 
level was observed in any cell line relative to parental MCF-7 cells.  
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Figure 9. Observed increase of SMAD-dependent TGF-β signalling in ΔCD cells 
resulted in increase of SLC39A1 and decrease of BST2 expression in ΔCD 
cells.  
Genes previously known to be up- or down-regulated by TGF-β signalling were analyzed 
with qPCR. SLC39A1, CDKN1A, and EHF have been shown to be upregulated through 
the canonical TGF-β/SMAD pathway. Increased expression of SLC39A1 (p<0.01) and 
EHF (p<0.01) were observed in ΔCD and C1 cells, respectively. No change in CDKN1A 
expression occurred in either cell line. Conversely, BST2 and TP53INP1 were previously 
observed to be downregulated following TGF-β treatment. Expression of BST2 
significantly decreased in C1 (p<0.001) and ΔCD (p<0.0001) cells, with no change 
observed in TP53INP1 expression. Three biological replicates are shown as log2 
transformed mean fold-change ± SEM and were compared using one-way ANOVA and 
Tukey’s post-hoc test; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.  
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4 DISCUSSION 
The aim of this study was to generate a catalog of proteins that associate with MT1-MMP 
to corroborate previous research of MT1-MMP-mediated proteolytic and cell signalling 
functions. Using MCF-7 breast cancer cells, stable cell lines were previously created that 
overexpress MT1-MMP (C1) or express MT1-MMP lacking its cytoplasmic domain 
(ΔCD). I hypothesized that the diverse functions of MT1-MMP are dependent on 
domain-specific binding partners that elucidate a cellular response. The first objective of 
the study was to identify putative MT1-MMP binding partners, and 248 unique proteins 
were isolated following MT1-MMP pulldown and identified with mass spectrometry. 
Secondly, comparison of binding partners isolated from full-length and truncated 
MT1-MMP expressing cells identified differences in KEGG pathway enrichment. In 
particular, the cytoplasmic domain may be required for protein-protein interactions that 
facilitate MT1-MMP localization. Finally, the cytoplasmic domain of MT1-MMP is 
involved in cell signalling pathways as indicated by an increase in canonical TGF-β 
signalling within ΔCD cells.  
4.1 Identification of MT1-MMP binding partners and similarities to previous 
MT1-MMP proteomic research 
In this study, 248 proteins (Appendix B) were coimmunoprecipitated with MT1-MMP 
and identified via mass spectrometry in parental MCF-7, C1, and ΔCD cells. Although 
939 proteins were identified in MCF-7 cells, 919 in C1 cells, and 1051 in ΔCD, stringent 
filtering criteria was used to eliminate non-specific proteins. Firstly, proteins needed to be 
identified by at least 1 unique peptide and isolated in ³2 biological replicates. Second, 
pulldown with a rabbit IgG antibody was used as a negative control to identify proteins 
that may non-specifically associate with the MT1-MMP rabbit antibody or beads. Third, 
ribosomes and proteins that were associate with the spliceosome pathway (Appendix A) 
were removed due to their identification as common contaminants (Gingras et al., 2007). 
Ribosomal and spliceosome-related proteins were also observed to be enriched in the 
anti-rabbit IgG pulldown. Following removal of non-specific proteins, the final dataset 
included ~15% of the total number of proteins that were originally isolated with 
anti-MT1-MMP immunoprecipitation (Figure 5a). Since label-free 
 
 
55 
5
5
 
coimmunoprecipitation relies on a single step affinity purification, it is estimated that true 
interaction partners represent ~10% of originally identified proteins (Nesvizhskii, 2012). 
The number of true interactions being 15% of the total number of proteins originally 
isolated in this study is within this magnitude. 
In the identification of false positives, many proteins are recognized as common 
contaminants and subsequently excluded from analysis. Typically, these proteins are 
highly abundant (e.g. tubulins and actins) or involved in disrupted protein folding (e.g. 
heat shock proteins and chaperones) (Gingras et al., 2007; Nesvizhskii, 2012). Highly 
abundant proteins, and those involved in disrupted protein folding, were isolated with 
MT1-MMP. However, a limitation of affinity purification and mass spectrometry is its 
inability to decipher a multiplicity of associations (Gingras et al., 2007). These proteins 
can have dramatically different roles as determined by which distinct, yet biologically 
relevant, complex they are associated with. For this reason, these proteins (e.g. tubulins, 
actin, or HSPs) were not removed from the dataset even though they are commonly 
identified as false positives.   
Several studies have identified MT1-MMP binding partners using a bottom-up proteomic 
approach. From this, approximately 400 unique proteins have been catalogued as 
potential MT1-MMP binding partners (Butler et al., 2008; Hwang et al., 2004; Niiya et 
al., 2009; Stegemann et al., 2013; Tam et al., 2004; Tomari et al., 2009). In agreement 
with previous studies, 26 of the 248 proteins identified here have been reported as MT1-
MMP binding partners (Table 4). These proteins include extracellular matrix components 
(laminin and vitronectin), receptors (transferrin receptor and receptor of activated protein 
C kinase), and various signalling molecules (G proteins). The catalog of binding partners 
identified in MT1-MMP proteomic studies contains approximately 400 proteins. 
However, complete lists of binding partners were not provided in all studies which 
indicates this catalog is much larger. For instance, Tam et al., (2004) provided only a 
subset of 17 identified binding partners whereas their original dataset contained over 100 
proteins. Similarly, Butler et al., (2008) only considered biochemically validated proteins.  
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Table 4. Proteins identified in this study that have been previously identified in 
other proteomic-based MT1-MMP studies.  
UniProtKB 
Accession 
Number Protein Name Reference(s) 
O15230 Laminin subunit alpha-5  1 
O43291 Kunitz-type protease inhibitor 2  2, 4 
O60884 DnaJ homolog subfamily A member 2  3 
O95816 BAG family molecular chaperone regulator 2  3 
P02765 Alpha-2-HS-glycoprotein 5 
P02786 Transferrin receptor protein 1 3, 4 
P04004 Vitronectin  5 
P04843 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1  
3 
P05023 Sodium/potassium-transporting ATPase subunit alpha-1  3 
P08107 Heat shock 70 kDa protein 1A/1B  4 
P08195 4F2 cell-surface antigen heavy chain  3 
P08754 Guanine nucleotide-binding protein G(k) subunit alpha  4 
P10909 Clusterin  5 
P11021 78 kDa glucose-regulated protein  3, 4 
P31689 DnaJ homolog subfamily A member 1  3, 4 
P35221 Catenin alpha-1  3, 4 
P35222 Catenin beta-1  4 
P50402 Emerin  4 
P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  
subunit beta-1  
3 
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 
(Receptor of activated protein C kinase 1) 
4 
 
P78371 T-complex protein 1 subunit beta  3 
Q01650 Large neutral amino acids transporter small subunit 1  3 
Q13162 Peroxiredoxin-4  3 
Q13501 Sequestosome-1  3, 4 
Q9BUF5 Tubulin beta-6 chain  3 
Q9UIQ6 Leucyl-cystinyl aminopeptidase  3 
1 Stegemann et al., 2013; 2 Butler et al., 2008; 3 Tomari et al., 2009; 4 Niiya et al., 2009;             
5 Hwang et al., 2004  
No accession numbers were provided in Niiya et al., 2009. 
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Finally, Niiya et al., (2009) did not provide accession numbers of the proteins identified 
in the study. Due to the historically unpredictable nature of protein naming, a proper 
comparison could not be completed. 
It is important to note that although only ~10% of proteins pulled down in this study have 
been previously identified, the affinity purification methodology employed in this work 
differed drastically. In previous studies, the use of tagged MT1-MMP (for easy isolation) 
or catalytically inactive MT1-MMP (to prevent degradation of binding partners) could 
alter MT1-MMP–protein complex formation, unlike native MT1-MMP used in this study.  
4.2 Validation of select binding partners 
As 248 proteins were identified by mass spectrometry as putative MT1-MMP binding 
partners, I sought to validate the utility of the co-immunoprecipitation. Pulldown of 
MT1-MMP followed by immunoblot analysis confirmed MT1-MMP interactions with 
vitronectin, hyaluronan-mediated motility receptor, and fragile X mental retardation 
protein 1 (Figure 6).  
Vitronectin is a multifunctional extracellular glycoprotein commonly involved in 
cell-ECM adhesion. MT1-MMP mediated degradation of vitronectin was previously 
observed in human plasma incubated with a soluble MT1-MMP catalytic domain (Hwang 
et al., 2004). While observed in parental cells, vitronectin was not identified following 
MT1-MMP pulldown from ΔCD cells by mass spectrometry nor immunoblotting 
(Appendix B, Figure 6). This is not due to an inability of MT1-MMP to digest vitronectin 
as MT1-MMP lacking its transmembrane and cytoplasmic domain cleaved vitronectin 
into two distinct fragments (Ohuchi et al., 1997). Rather, improper localization or 
recycling of ΔCD MT1-MMP (section 4.4.3) could result in perpetual inhibition by 
TIMP-2 or other endogenous inhibitors. Although identified by mass spectrometry 
following MT1-MMP pulldown in C1 cells, no visible band corresponding to vitronectin 
was observed in the validation assay (Figure 6). Due to increased MT1-MMP expression 
in C1 cells, these cells have higher levels of ECM degradation. For this reason, 
vitronectin bound to MT1-MMP may be rapidly degraded to a level undetectable by 
immunoblot analysis.  
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The hyaluronan-mediated motility receptor belongs to a family of hyaladherins that share 
the ability to bind hyaluronic acid (HA), an important component of the ECM and tumour 
microenvironment. Despite its putative extracellular role, there are reports that 
intracellular HMMR is involved in mitotic spindle integrity and cell cycle progression 
(Entwistle et al., 1996). In this study, HMMR was isolated in parental MCF-7, C1, and 
ΔCD cell lines. This alludes that the interaction with MT1-MMP is most likely occurring 
at the cell surface and supports an extracellular role (Figure 6, Appendix B). This study is 
the first to report a direct interaction between HMMR and MT1-MMP. However, HMMR 
forms a complex with CD44 and HA on the cell surface to activate intracellular signalling 
pathways, in particular MAPK via ERK1/2 activation (Turley et al., 1993; Zhang et al., 
1998). The interaction between MT1-MMP and CD44 has been extensively reported, 
with localization of MT1-MMP to invadopodia and associated increase in cell migration 
attributed to this interaction (Mori et al., 2002; Ridley et al., 1992). Since MT1-MMP, 
CD44, and now purportedly HMMR can be clustered to invadopodia, both MT1-MMP 
hemopexin-mediated binding and proteolytic shedding of HMMR may contribute to the 
previously observed increase in ERK activation within these cell lines (Cepeda et al., 
2016, 2017b).  
MT1-MMP not only co-immunoprecipitated with FMR1, but also two homologs that 
interact with it: fragile X-related protein (FXR) 1 and FXR2 (Zhang et al., 1995; Figure 
6, Appendix B). To date, research of FMR1 focuses on its role as a translation regulator 
of proteins involved in cellular migration, motility, as well as adhesion and EMT (Lucá et 
al., 2013). In particular, FMR1 modulates the expression of MMP-8 as well as TIMP-2 
(Zalfa et al., 2017). For this reason, it is unsurprising that FMR1 is overexpressed in 
various cancer, correlating with aggressive breast cancer markers. Interaction of 
MT1-MMP with FMR1 or its homologs have not been previously reported. However, just 
as MT1-MMP is localized at the leading edge of migrating cells, FMR1 is also 
asymmetrically distributed with a front-rear polarity in cell migration (Zalfa et al., 2017). 
Validation of vitronectin, HMMR, and FMR1 co-immunoprecipitation with MT1-MMP 
further supports that other proteins identified in this study are true interactions. 
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4.3 Involvement of binding partners in different pathways highlights the 
diverse function of MT1-MMP 
KEGG analysis of MT1-MMP binding partners identified enrichment within various 
pathways (Table 2). Many of these networks have not been previously shown to involve 
MT1-MMP functions. Protein involved in endocrine and other factor-regulated calcium 
reabsorption pathways, pathogenic Escherichia coli infection, and Huntington’s disease 
pathways were enriched within the catalog of MT1-MMP pulldown proteins. Upon 
further examination, many of these proteins are part of cellular processes within the 
identified pathway. For example, adaptor proteins and clathrin are key proteins involved 
in endocytosis that may be dysfunctional within Huntington’s disease. Since KEGG 
pathway analysis treats each pathway as a separate entity, it ignores the effect of shared 
proteins involved in various cascades. For this reason, pathogenic E. coli infection, 
Huntington’s disease, and endocrine and other factor-regulated calcium reabsorption 
pathways are not necessarily indicative of MT1-MMP’s function within MCF-7 cells.  
Involvement of MT1-MMP in other pathways such as RNA transport, RNA degradation, 
and mRNA surveillance has also not been reported. However, MT1-MMP pulldown 
proteins enriched in these KEGG pathways relate to a role in mRNA degradation. Mostly 
centred around the nucleus, MT1-MMP binding partners (e.g. pinin/PNN) further support 
that MT1-MMP can be translocated to the nucleus. Although MT1-MMP has no clear 
nuclear localization sequence (NLS), furin recognition motifs between the pro- and 
catalytic domain represent a bipartite NLS (Strongin, 2006). MT1-MMP interaction with 
importin α implies that this method of transport to the nucleus may be occurring. 
However, it is unknown whether this mechanism would specify between the transport of 
pro- or active MT1-MMP. Regardless, MT1-MMP colocalizes with MMP-2 in nuclei of 
liver tumours, correlating with poor survival (Ip et al., 2007). Immunoblot analysis of 
nuclear MT1-MMP identified the 63 kDa active form as well as the 43 kDa degraded 
form generated by MMP-2 processing, verifying that MT1-MMP and MMP-2 are 
catalytically active within the nucleus. Additionally, Ip et al., (2007) observed 
MT1-MMP transport to the perinuclear region in a caveolin-dependent manner, similar to 
the nuclear translocation of insulin-like growth factor binding protein-3. Although the 
function of MT1-MMP within the nucleus isn’t fully characterized, isolation of binding 
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partners involved in mRNA degradation suggest a new potential role of MT1-MMP 
within the nucleus/perinuclear region. 
4.4 The cytoplasmic domain of MT1-MMP is required for protein export, 
processing in the endoplasmic reticulum, and endocytosis 
To better elucidate the role of domain-specific interactions, prey proteins isolated from 
full-length MT1-MMP expressing cells (MCF-7 and/or C1), but not ΔCD cells, were 
analyzed. KEGG pathway analysis identified enrichment within the 177 proteins isolated 
in MCF-7 and C1 cells that was not observed in the 71 proteins isolated in ΔCD cells 
(Figure 5). Of particular interest, there was an enrichment of proteins involved in protein 
export, protein processing in the endoplasmic reticulum, and endocytosis (Table 3).  
4.4.1 Protein export 
Approximately 30% of all translated proteins are delivered to the endoplasmic reticulum, 
most commonly by the signal recognition particle (SRP). Comprised of 6 proteins and a 
7S SRP RNA, the SRP can be divided into two distinct domains – Alu domain and S 
domains. Two different SRP proteins immunoprecipitated with MT1-MMP in the 
parental MCF-7 and C1 cell lines. Of particular interest, SRP14 is a subunit of the Alu 
domain whereas SRP72 is a subunit of the S domain (Akopian et al., 2013). No previous 
research has identified an interaction between MMPs and the SRP. In fact, there has been 
no reported protease involvement with the SRP. Since pro-MT1-MMP is commonly 
activated in the trans-Golgi network, this SRP interaction is likely not enzyme/substrate 
oriented. The lack of SRP components pulled down in ΔCD cells suggests that translation 
of the complete protein is required for this interaction to occur. As a type-1 
transmembrane protein, the cytoplasmic domain is translated last, with the other domains 
(pro, catalytic, and hemopexin) already present in the ER lumen. Translation of ΔCD 
MT1-MMP may not be completed properly due to the lack of expected charged amino 
acid residues that would be found in the cytoplasmic domain. The SRP may detect this 
anomaly. As a result, while the full-length protein remains bound to the SRP for further 
functions or processing, the truncated protein is not. 
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4.4.2 Protein processing within the ER 
In comparison with ΔCD, full-length MT1-MMP expressing cells co-immunoprecipitated 
various proteins associated with quality control in the endoplasmic reticulum (i.e. 
TRAPα, ribophorin 1, and Sec13). Translocon-associated protein subunit alpha (TRAPα) 
discriminately binds misfolded proteins for efficient degradation upon unfolded protein 
response (UPR) stimulation. TRAPα was isolated solely in C1 cells with a ~2500-fold 
increase in MT1-MMP expression. Proper folding of this abnormally high level of protein 
may be rate-limiting, and thus initiate the UPR. Under homeostatic conditions, however, 
the TRAP complex associates with the translocon to properly fold newly translated 
polypeptides (Ménétret et al., 2005). Another commonly associated translocon protein is 
dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (ribophorin 1) 
that facilitates N-glycosylation of newly synthesized proteins (Wilson et al., 2005). 
MT1-MMP has two potential N-glycosylation sites at Asn229 in the catalytic domain and 
Asn311 within the linker region (Boon et al., 2016). Although putative sequences are 
found, inhibition of N-glycosylation doesn’t affect the glycosylation status of MT1-MMP 
nor its cell surface localization (Remacle et al., 2006). Instead, ribophorin 1 interaction 
with MT1-MMP may be related to protein folding in the ER (Wilson et al., 2005).  
During translocation through the ER, MT1-MMP matures before transport to the Golgi 
for further processing. A common mechanism of ER-Golgi transport is via coat protein 
complex II (COPII)-coated vesicles. Interaction of full-length MT1-MMP with Sec13 
indicates that transport from the ER to Golgi occurs in this manner as Sec proteins are 
constituents of the COPII coat. Membrane proteins transported to the Golgi typically 
contain an ER-export motif, which is characterized for MT1-MMP (Nufer et al., 2002). 
The terminal valine of the cytoplasmic domain and dileucine motif near the C-terminus 
act as ER export signals (Nufer et al., 2002; Ureña et al., 1999). However, MT1-MMP 
lacking its cytoplasmic domain may still transport to the Golgi for further processing 
since Sec16, an early mediator of COPII vesicle formation, was pulled down with 
MT1-MMP in all cell lines (Hughes et al., 2009).  
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4.4.3 Endocytosis 
Endocytosis can regulate MT1-MMP activity by controlling the level of active 
MT1-MMP on the cell surface as well as by removing TIMP-bound or otherwise 
inhibited MT1-MMP from the surface. The LLY573 motif within the cytoplasmic domain 
interacts with AP-2 to mediate clathrin-driven endocytosis (Uekita et al., 2001). Previous 
research of the ΔCD cell line observed that cytoplasmic deletion increased the migration 
of the cells in multiple assays (Cepeda et al., 2017b). Since ΔCD MT1-MMP mutants are 
unable to activate MMP-2 nor degrade gelatin (Cepeda et al., 2017b), the increase in cell 
migration is likely due to non-proteolytic mechanisms. This reduction in catalytic activity 
may be related to the absence of clathrin-related machinery pulled down in ΔCD cells. 
Since the MT1-MMP catalytic domain is rapidly inactivated by binding of TIMP-2 and 
other inhibitors, surface-localized proteolytic function of MT1-MMP relies on a constant 
supply of active MT1-MMP (Remacle et al., 2006). This supply is not solely dependent 
on the biosynthetic pathway. Instead, endocytosed MT1-MMP can be recycled back to 
the membrane during which any bound inhibitors dissociate. It appears that since ΔCD 
MT1-MMP cannot bind endocytic machinery, ΔCD MT1-MMP is not properly 
endocytosed via clathrin-coated vesicles. This reduction of endocytosis corroborates 
previous observations that ΔCD MT1-MMP has punctate localization at the cell surface, 
yet is unable to activate MMP-2 or degrade gelatin.  
Following endocytosis, recycling of MT1-MMP to invasive protrusions of the plasma 
membrane involves Rab GTPases. Rab GTPases are a family of Ras-related GTPases that 
determine the specificity of vesicle transport. Rab-4, 5A, 7, and 8 co-localize with 
MT1-MMP-positive vesicles and have been identified as regulatory components of 
MT1-MMP exocytosis from the late endosome to invadopodia (Castro-Castro et al., 
2016). There are no reports regarding Rab10 and MT1-MMP recycling, however, Rab10 
is closely related to Rab8. Rab8 is known to regulate polarized membrane transport to 
invasive structures in MDA-MB-231 cells (Bravo-Cordero et al., 2007). Intracellular 
MT1-MMP is compartmentalized in Rab8-positive vesicles to control cell surface 
activity, but mobilized to the surface when cells are actively degrading the ECM (Bravo-
Cordero et al., 2007). This trafficking would mimic other membrane proteins that are 
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retained intracellularly, but redistributed via Rab10 to the plasma membrane upon 
stimulation (Sano et al., 2007). Due to the similarity in structure and vesicle localization, 
Rab8 and Rab10 may share similar roles in the recycling of MT1-MMP to the cell 
surface, especially since they are upregulated in cancer cells (He et al., 2002; Ip et al., 
2007). The cytoplasmic domain is required for proper MT1-MMP endocytosis and 
recycling through its interaction with AP-2, clathrin, and Rab GTPases. 
The cytoplasmic domain has been previously identified as a requirement for proper MT1-
MMP endocytosis, this may be due to truncated MT1-MMP being unable to interact with 
AP-2, clathrin, or Rab GTPases.  
4.5 Limitations of affinity-purified mass spectrometry 
Although many proteins discovered in this analysis have been previously reported to 
immunoprecipitated with MT1-MMP, some, such as MMP-2 (Will et al., 1996), CD44 
(Kajita et al., 2001), or TIMP-2 (Will et al., 1996), were not isolated here. Due to the 
sensitivity of mass spectrometry, extensive purification measures are required to remove 
impurities and reduce the number of false positives. This is done at risk of losing weak 
interactions that are biologically relevant (Vermeulen et al., 2008). During the 
mechanical and chemical stresses of co-immunoprecipitation, bait-prey interactions may 
be lost if the interaction is low-affinity or transient (Gingras et al., 2007). The affinity and 
strength of an interaction is dictated by the type of bonds that form. For MT1-MMP, 
hydrogen bonds form between its catalytic domain and substrate whereas covalent or 
noncovalent bonds can form at other MT1-MMP domains (Overall, 2001). Accordingly, 
catalytic binding partners such as MMP-2 and TIMP-2 would be more difficult to capture 
than proteins that bind other MT1-MMP domains. 
In addition to loss of protein-protein interactions during purification procedures, 
commonly identified binding partners may be absent in the final dataset due to cell-type 
specificity. In previous MT1-MMP proteomic studies, 163 and 158 proteins were 
coimmunoprecipitated from A431 carcinoma and A375 melanoma cells, respectively. 
Experimental procedures were identical in these studies, but only 61 proteins were shared 
between them (Niiya et al., 2009; Tomari et al., 2009). It appears that the sensitivity of 
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mass spectrometry is affected by sample complexity, with highly abundant proteins being 
favoured. Although less common than false positives, false negatives typically occur 
because of this reason; since interactions with lowly abundant proteins can masked by 
highly abundant protein. Due to low abundance of MMP-2 and TIMP-2 in MCF-7 cells 
(Cepeda et al., 2017a), the likelihood of pulldown with MT1-MMP is reduced. Similarly, 
because the mass spectrometer operated using a FT/IT/CID Top 10 data-dependent mode, 
highly abundant proteins are more likely to be identified than lowly abundant proteins. 
Cell-type specific expression may explain why commonly reported MT1-MMP binding 
partners (e.g. MMP-2 and TIMP-2) were not identified in this study as well as previous 
studies (Niiya et al., 2009; Tomari et al., 2009).  
Samples submitted for mass spectrometry are complex and provide a snapshot of 
MT1-MMP interactions at the time of protein isolation. If the MT1-MMP–protein 
interaction is weak, it may be lost during affinity purification procedures. In contrast, if 
the cell has low expression of a binding partner, the interaction may not be occurring at 
the time of cell lysate collection or it may be masked by higher abundant proteins during 
mass spectrometry analysis. These issues highlight a disadvantage of unlabelled affinity 
purification and mass spectrometry analysis: reproducibility between individual sample 
preparations. In a previous MT1-MMP proteomic analysis, Butler et al., (2008) identified 
269 different proteins from 3 biological replicates. However, of those 269 proteins, 65% 
were identified in only one biological replicate, 28% were identified in two, and 7% were 
identified in all three. Indeed, even in this present study, known MT1-MMP binding 
proteins were identified (i.e. collagen 1α and TIMP-3), but only isolated within one 
biological replicate. Since the criteria of a true interaction required isolation from ³2 
biological replicates, these proteins were subsequently removed.  
4.6 The cytoplasmic domain of MT1-MMP attenuates TGF-β signalling in 
MCF-7 cells  
MT1-MMP lacking its cytoplasmic domain has reduced proteolytic activity, yet ΔCD 
cells, but not C1, were more migratory than parental MCF-7 cells (Cepeda et al., 2016, 
2017b). This indicates that MT1-MMP has a non-proteolytic role in cell migration. 
Increased migration of ΔCD cells is not due to changes in gene expression commonly 
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observed in epithelial-mesenchymal transition (Figure 7a). However, a decrease in 
TGFB1 expression was observed in ΔCD cells. Therefore, an objective of the study was 
to identify any potential roles of the MT1-MMP cytoplasmic domain regarding cell 
signalling pathways, in particular TGF-β signalling.  
Originally, no change in intracellular small latency complex-bound TGF-β1 protein level 
was observed (Figure 7b). However, no suitable TGF-β1 antibody, of the three utilized, 
specifically corresponded with TGF-β1 or its associated complexes. Furthermore, 
TGF-β1 is a secreted cytokine that is released from inhibitory complexes in the ECM 
before it can function as a ligand. Thus, whole cell lysate used for immunoblot analysis 
would not be indicative of extracellular TGF-β1 protein level. For this reason, 
quantifying the level of intracellular SLC-bound TGF-β1 protein is not representative of 
TGF-β1 protein level. In an attempt to quantify extracellular TGF-β1 protein level, cell 
media was protein precipitated and immunoblotted. However, this was not successful. 
Thus, SMAD2 phosphorylation was used to better understand if a reduction of TGFB1 
resulted in a decrease in canonical TGF-β signalling 
Altered levels of TGF-β genes in ΔCD cells ultimately resulted in increased 
SMAD-dependent TGF-β signalling (Figure 8). Previously observed genes regulated by 
TGF-β signalling had variable expression in ΔCD cells (Figure 9). However, expected 
changes in response to increased TGF-β signalling were observed in some genes (e.g. 
SLC39A1 and BST2). Other genes examined that did not change solely due to increased 
SMAD-dependent TGF-β signalling may be modulated by multiple signalling pathways.  
Altered TGF-β signalling is likely to occur through MT1-MMP-mediated liberation of 
extracellular TGF-β isoforms from their inhibitory complexes (Nguyen et al., 2016). 
MT1-MMP can cleave latent TGF-β binding proteins directly, but also indirectly through 
pro-MMP-2 and pro-MMP-9 activation (Yu and Stamenkovic, 2000). However, MCF-7 
cells are naturally deficient in MMP-2 and MMP-9 expression. Additionally, MT1-MMP 
proteolytic activity in ΔCD cells is ablated (Cepeda et al., 2017b). For these reasons, 
increased SMAD2 phosphorylation is likely not a result of increased free TGF-β ligand 
that can bind its receptors. Rather, reduced MT1-MMP proteolytic activity in ΔCD cells 
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maintains TGF-β receptor 3 (TGFβR3, betaglycan) at the cell surface. In contrast, 
MT1-MMP in parental MCF-7 and C1 cells may shed TGF-β receptors, such as 
betaglycan, from the cell surface (Velasco-Loyden et al., 2004). When bound to the 
plasma membrane, betaglycan functions as a coreceptor, enhancing TGFβ affinity with 
TGFβR2 to facilitate downstream signalling. However, when shed from the membrane, 
betaglycan has an inverse effect by inhibiting TGF-β availability, especially the TGF-β2 
isoform (López-Casillas et al., 1994; Velasco-Loyden et al., 2004). Reduced ΜΤ1-ΜΜP 
catalytic activity in ΔCD cells (Cepeda et al., 2017b) would prevent betaglycan shedding, 
thus increasing TGF-β signalling relative to parental MCF-7 and C1 cells. 
4.7 Future directions 
The work presented is a strong foundation on which future data mining of MT1-MMP 
interacting partners and networks can be accomplished. To begin, although proteins 
pulled down with MT1-MMP indicate an association, the functional consequences of the 
interaction are unknown. The comparison of proteins isolated from full-length expressing 
MT1-MMP cells with proteins isolated in ΔCD cells can help elucidate, but not confirm, 
the outcome of an interaction. To that end, characterization of domain-specific binding, 
cellular localization, and the outcome of an interaction regarding cell signalling or 
degradation by-products should be evaluated first. Future work should aim to better 
understand the translation of an MT1-MMP–protein interaction to other in vitro and in 
vivo approaches. The MCF-7 cell line used in this study has low endogenous expression 
of MT1-MMP. As such, overexpression of MT1-MMP may result in nonphysiologically 
relevant MT1-MMP–protein interactions. An interaction should be confirmed using 
another cell type, such as MDA-MB 231 cells, that have higher endogenous MT1-MMP 
expression than MCF-7 cells. Additionally, since MT1-MMP remodels the ECM, in vitro 
conditions such as growth on a synthetic ECM may impact the location and outcome of 
an interaction. Finally, a transition from in vitro to in vivo studies would provide a more 
comprehensive understanding of MT1-MMP function as dictated by its interaction with 
various binding partners. 
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5 CONCLUSION 
Membrane-type 1 matrix metalloproteinase is a multifunctional enzyme involved in a 
variety of cellular processes. As previous studies have identified binding partners of 
MT1-MMP that contribute to its diverse function, the aim of this study was to generate a 
catalog of proteins that associate with MT1-MMP to corroborate previous research 
regarding the role of MT1-MMP in cell migration, invasion, and survival. Here, 248 
proteins were isolated with MT1-MMP in MCF-7 cells, 26 of which have been 
previously reported as MT1-MMP binding partners. Binding partners identified within 
this study imply new putative MT1-MMP functions, such as RNA turnover or transport. I 
hypothesized that these binding partner interactions, and subsequent cellular responses, 
are MT1-MMP domain-specific. In this study, binding partners isolated from full-length 
expressing MT1-MMP cells were compared with those isolated from cells that express a 
truncated form of MT1-MMP lacking its cytoplasmic domain. KEGG enrichment analysis 
suggests the cytoplasmic domain may be required for protein-protein interactions that 
facilitate MT1-MMP function, such as proper processing in the ER, protein export, and 
endocytosis. However, ΔCD cells have increased SMAD2 phosphorylation, indicating 
that the cytoplasmic domain of MT1-MMP may attenuate canonical transforming growth 
factor beta (TGF-β) signalling through an unknown mechanism. By contributing to the 
expanding catalog of MT1-MMP binding partners, this work suggests new MT1-MMP 
functions within MCF-7 cells.  
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Appendix A. Top 10 most significantly enriched KEGG pathways represented by 266 proteins co-immunoprecipitated with 
MT1-MMP in parental MCF-7, C1, and ΔCD. 
ID: KEGG Pathway Count Size Genes FDR 
hsa03040: Spliceosome 19 130 CDC5L DDX5 DHX15 EIF4A3 HSPA1A 2.53 x 10-11 
PCBP1 PLRG1 PRPF19 PRPF8 RBMX 
RBMXL1 RP9 SART1 SF3B4 SNW1 
SRSF10 SRSF3 SRSF9 TRA2B  
hsa03013: RNA transport 19 159 CASC3 EIF2S1 EIF2S3 EIF3C EIF3CL 3.21 x 10-10 
EIF3I EIF4A1 EIF4A3 EIF4G1 FMR1 
FXR1 FXR2 NUP210 PABPC1 PABPC4 
PNN RAN SEC13 UPF1  
hsa03018: RNA 
degradation 
12 77 CNOT1 CNOT2 CNOT3 CNOT7 DDX6 1.49 x 10-7 
DHX36 EDC4 HSPA9 HSPD1 PABPC1 
PABPC4 XRN2    
hsa03015: mRNA 
surveillance pathway 
12 89 CASC3 CPSF1 CPSF2 EIF4A3 FIP1L1 4.87 x 10-7 
PABPC1 PABPC4 PNN PPP1CA PPP1CC 
UPF1 WDR33    
hsa04141: Protein 
processing in the 
endoplasmic reticulum 
12 161 BAG2 DNAJA1 DNAJA2 EIF2S1 HSP90AA1 0.00014 
HSP90AB
1 
HSPA1A HSPA5 RPN1 RRBP1 
SEC13 SSR1    
hsa05130: Pathogenic 
Escherichia coli infection 
7 53 CTNNB1 NCL TUBB2A TUBB2B TUBB6 0.00045 
YWHAQ YWHAZ    
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(Appendix A continued)    
ID: KEGG Pathway Count Size Genes FDR 
hsa05016: Huntington’s 
disease 
10 193 AP2A1 AP2B1 AP2M1 ATP50 ATP5A1 0.011 
ATP5C1 CLTC DCTN1 NDUFA4 SLC25A5 
hsa04961: Endocrine and 
other factor-regulated 
calcium reabsorption  
5 47 AP2A1 AP2B1 AP2M1 ATP1A1 CLTC 0.0144 
hsa04261: Adrenergic 
signaling in cardiomyocytes 
8 139 ATP1A1 ATP2A2 CALM1 GNAI3 PPP1CA 0.0167 
PPP1CC TPM1 TPM3   
hsa03450: Non-homologous 
end-joining 
3 13 PRKDC XRCC5 XRCC6   0.0209 
 
Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate 
Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway 
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Appendix B. Final list of 248 MT1-MMP associating proteins identified by LC-MS/MS within MCF-7 cell lines.  
UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
B5ME19 EIFCL Eukaryotic translation initiation factor 3 subunit C-like protein  + – – 
O00468 AGRIN Agrin  + – – 
O00567 NOP56 Nucleolar protein 56  + – – 
O14545 TRAD1 TRAF-type zinc finger domain-containing protein 1  + – – 
O15230 LAMA5 Laminin subunit alpha-5  + – – 
O15234 CASC3 Protein CASC3  + – – 
O60264 SMCA5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5  + – – 
O60884 DNJA2 DnaJ homolog subfamily A member 2  + – – 
O75534 CSDE1 Cold shock domain-containing protein E1  + – – 
O76094 SRP72 Signal recognition particle subunit SRP72  + – – 
O95047 OR2A4 Olfactory receptor 2A4  + – – 
O95782 AP2A1 AP-2 complex subunit alpha-1  + – – 
O95816 BAG2 BAG family molecular chaperone regulator 2  + – – 
O96019 ACL6A Actin-like protein 6A  + – – 
P05198 IF2A Eukaryotic translation initiation factor 2 subunit 1  + – – 
P07900 HS90A Heat shock protein HSP 90-alpha  + – – 
P07951 TPM2 Tropomyosin beta chain  + – – 
P08754 GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha  + – – 
P09493 TPM1 Tropomyosin alpha-1 chain  + – – 
P10809 CH60 60 kDa heat shock protein mitochondrial  + – – 
P19338 NUCL Nucleolin  + – – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
P31689 DNJA1 DnaJ homolog subfamily A member 1  + – – 
P36873 PP1G Serine/threonine-protein phosphatase PP1-gamma catalytic subunit  + – – 
P41091 IF2G Eukaryotic translation initiation factor 2 subunit 3  + – – 
P42166 LAP2A Lamina-associated polypeptide 2 isoform alpha  + – – 
P49411 EFTU Elongation factor Tu mitochondrial  + – – 
P50402 EMD Emerin  + – – 
P55265 DSRAD Double-stranded RNA-specific adenosine deaminase  + – – 
P60842 IF4A1 Eukaryotic initiation factor 4A-I  + – – 
P61158 ARP3 Actin-related protein 3  + – – 
P62136 PP1A Serine/threonine-protein phosphatase PP1-alpha catalytic subunit  + – – 
P62873 GBB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  + – – 
P62879 GBB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2  + – – 
P63104 1433Z 14-3-3 protein zeta/delta  + – – 
P78371 TCPB T-complex protein 1 subunit beta  + – – 
P78527 PRKDC DNA-dependent protein kinase catalytic subunit  + – – 
Q02241 KIF23 Kinesin-like protein KIF23  + – – 
Q13601 KRR1 KRR1 small subunit processome component homolog  + – – 
Q14498 RBM39 RNA-binding protein 39  + – – 
Q14694 UBP10 Ubiquitin carboxyl-terminal hydrolase 10  + – – 
Q15149 PLEC Plectin  + – – 
Q15637 SF01 Splicing factor 1  + – – 
Q5JSZ5 PRC2B Protein PRRC2B  + – – 
Q5T200 ZC3HD Zinc finger CCCH domain-containing protein 13  + – – 
Q5VZF2 MBNL2 Muscleblind-like protein 2  + – – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q6P158 DHX57 Putative ATP-dependent RNA helicase DHX57  + – – 
Q6P2E9 EDC4 Enhancer of mRNA-decapping protein 4  + – – 
Q6PJW8 CNST Consortin  + – – 
Q8IWZ3 ANKH1 Ankyrin repeat and KH domain-containing protein 1  + – – 
Q8IY17 PLPL6 Neuropathy target esterase  + – – 
Q8NE71 ABCF1 ATP-binding cassette sub-family F member 1  + – – 
Q8TDD1 DDX54 ATP-dependent RNA helicase DDX54  + – – 
Q92615 LAR4B La-related protein 4B  + – – 
Q92928 RAB1C Putative Ras-related protein Rab-1C  + – – 
Q96AG4 LRC59 Leucine-rich repeat-containing protein 59  + – – 
Q96JQ0 PCD16 Protocadherin-16  + – – 
Q96PK6 RBM14 RNA-binding protein 14  + – – 
Q99613 EIF3C Eukaryotic translation initiation factor 3 subunit C  + – – 
Q9BU76 MMTA2 Multiple myeloma tumor-associated protein 2  + – – 
Q9BUF5 TBB6 Tubulin beta-6 chain  + – – 
Q9BWE0 REPI1 Replication initiator 1  + – – 
Q9BWF3 RBM4 RNA-binding protein 4  + – – 
Q9BYJ9 YTHD1 YTH domain family protein 1  + – – 
Q9H0C5 BTBD1 BTB/POZ domain-containing protein 1  + – – 
Q9H0D6 XRN2 5'-3' exoribonuclease 2  + – – 
Q9H0U4 RAB1B Ras-related protein Rab-1B  + – – 
Q9H307 PININ Pinin  + – – 
Q9NR56 MBNL1 Muscleblind-like protein 1  + – – 
Q9P1U1 ARP3B Actin-related protein 3B  + – – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q9UIQ6 LCAP Leucyl-cystinyl aminopeptidase  + – – 
Q9UIV1 CNOT7 CCR4-NOT transcription complex subunit 7  + – – 
Q9UKV8 AGO2 Protein argonaute-2  + – – 
Q9UPT8 ZC3H4 Zinc finger CCCH domain-containing protein 4  + – – 
Q9Y446 PKP3 Plakophilin-3  + – – 
O00483 NDUA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  – + – 
O43291 SPIT2 Kunitz-type protease inhibitor 2  – + – 
O43852 CALU Calumenin  – + – 
O75909 CCNK Cyclin-K  – + – 
O94972 TRI37 E3 ubiquitin-protein ligase TRIM37  – + – 
P02765 FETUA Alpha-2-HS-glycoprotein  – + – 
P02786 TFR1 Transferrin receptor protein 1  – + – 
P05023 AT1A1 Sodium/potassium-transporting ATPase subunit alpha-1  – + – 
P07814 SYEP Bifunctional glutamate/proline--tRNA ligase  – + – 
P10909 CLUS Clusterin  – + – 
P16615 AT2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  – + – 
P35221 CTNA1 Catenin alpha-1  – + – 
P40938 RFC3 Replication factor C subunit 3  – + – 
P40939 ECHA Trifunctional enzyme subunit alpha mitochondrial  – + – 
P43307 SSRA Translocon-associated protein subunit alpha  – + – 
P48047 ATPO ATP synthase subunit O mitochondrial  – + – 
P53007 TXTP Tricarboxylate transport protein mitochondrial  – + – 
P54886 P5CS Delta-1-pyrroline-5-carboxylate synthase  – + – 
P55084 ECHB Trifunctional enzyme subunit beta mitochondrial  – + – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
P62820 RAB1A Ras-related protein Rab-1A  – + – 
P62826 RAN GTP-binding nuclear protein Ran  – + – 
Q00610 CLH1 Clathrin heavy chain 1  – + – 
Q01650 LAT1 Large neutral amino acids transporter small subunit 1  – + – 
Q08J23 NSUN2 tRNA (cytosine(34)-C(5))-methyltransferase  – + – 
Q10570 CPSF1 Cleavage and polyadenylation specificity factor subunit 1  – + – 
Q13885 TBB2A Tubulin beta-2A chain  – + – 
Q14244 MAP7 Ensconsin  – + – 
Q14566 MCM6 DNA replication licensing factor MCM6  – + – 
Q14C86 GAPD1 GTPase-activating protein and VPS9 domain-containing protein 1  – + – 
Q15773 MLF2 Myeloid leukemia factor 2  – + – 
Q16891 IMMT Mitochondrial inner membrane protein  – + – 
Q7Z6E9 RBBP6 E3 ubiquitin-protein ligase RBBP6  – + – 
Q86X29 LSR Lipolysis-stimulated lipoprotein receptor  – + – 
Q8NF37 PCAT1 Lysophosphatidylcholine acyltransferase 1  – + – 
Q8TB61 S35B2 Adenosine 3'-phospho 5'-phosphosulfate transporter 1  – + – 
Q8WXE9 STON2 Stonin-2  – + – 
Q96FJ2 DYL2 Dynein light chain 2 cytoplasmic  – + – 
Q9BVA1 TBB2B Tubulin beta-2B chain  – + – 
Q9C0J8 WDR33 pre-mRNA 3' end processing protein WDR33  – + – 
Q9P2E9 RRBP1 Ribosome-binding protein 1  – + – 
Q9P2I0 CPSF2 Cleavage and polyadenylation specificity factor subunit 2  – + – 
Q9UBM7 DHCR7 7-dehydrocholesterol reductase  – + – 
Q9Y5T5 UBP16 Ubiquitin carboxyl-terminal hydrolase 16  – + – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q8N163 CCAR2 Cell cycle and apoptosis regulator protein 2  – – + 
Q9NR30 DDX21 Nucleolar RNA helicase 2  – – + 
A5YKK6 CNOT1 CCR4-NOT transcription complex subunit 1  + + – 
O75175 CNOT3 CCR4-NOT transcription complex subunit 3  + + – 
O95793 STAU1 Double-stranded RNA-binding protein Staufen homolog 1  + + – 
P04004 VTNC Vitronectin  + + – 
P04843 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1  + + – 
P08195 4F2 4F2 cell-surface antigen heavy chain  + + – 
P08238 HS90B Heat shock protein HSP 90-beta  + + – 
P11021 GRP78 78 kDa glucose-regulated protein  + + – 
P11586 C1TC C-1-tetrahydrofolate synthase cytoplasmic  + + – 
P12956 XRCC6 X-ray repair cross-complementing protein 6  + + – 
P13010 XRCC5 X-ray repair cross-complementing protein 5  + + – 
P35222 CTNB1 Catenin beta-1  + + – 
P37108 SRP14 Signal recognition particle 14 kDa protein  + + – 
P38646 GRP75 Stress-70 protein mitochondrial  + + – 
P42167 LAP2B Lamina-associated polypeptide 2 isoforms beta/gamma  + + – 
P47756 CAPZB F-actin-capping protein subunit beta  + + – 
P48634 PRC2A Protein PRRC2A  + + – 
P51532 SMCA4 Transcription activator BRG1  + + – 
P52292 IMA1 Importin subunit alpha-1  + + – 
P55735 SEC13 Protein SEC13 homolog  + + – 
P61026 RAB10 Ras-related protein Rab-10  + + – 
P62158 CALM Calmodulin  + + – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
P63010 AP2B1 AP-2 complex subunit beta  + + – 
P69905 HBA Hemoglobin subunit alpha  + + – 
P84085 ARF5 ADP-ribosylation factor 5  + + – 
Q00577 PURA Transcriptional activator protein Pur-alpha  + + – 
Q09666 AHNK Neuroblast differentiation-associated protein AHNAK  + + – 
Q13148 TADBP TAR DNA-binding protein 43  + + – 
Q13162 PRDX4 Peroxiredoxin-4  + + – 
Q14145 KEAP1 Kelch-like ECH-associated protein 1  + + – 
Q14157 UBP2L Ubiquitin-associated protein 2-like  + + – 
Q14203 DCTN1 Dynactin subunit 1  + + – 
Q14247 SRC8 Src substrate cortactin  + + – 
Q14596 NBR1 Next to BRCA1 gene 1 protein  + + – 
Q16698 DECR 2 4-dienoyl-CoA reductase mitochondrial  + + – 
Q562R1 ACTBL Beta-actin-like protein 2  + + – 
Q68CP9 ARID2 AT-rich interactive domain-containing protein 2  + + – 
Q6NXG1 ESRP1 Epithelial splicing regulatory protein 1  + + – 
Q6PJT7 ZC3HE Zinc finger CCCH domain-containing protein 14  + + – 
Q6UN15 FIP1 Pre-mRNA 3'-end-processing factor FIP1  + + – 
Q71RC2 LARP4 La-related protein 4  + + – 
Q7L2E3 DHX30 Putative ATP-dependent RNA helicase DHX30  + + – 
Q7Z2W4 ZCCHV Zinc finger CCCH-type antiviral protein 1  + + – 
Q8NCA5 FA98A Protein FAM98A  + + – 
Q8TEM1 PO210 Nuclear pore membrane glycoprotein 210  + + – 
Q92900 RENT1 Regulator of nonsense transcripts 1  + + – 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q96B96 TM159 Promethin  + + – 
Q96CW1 AP2M1 AP-2 complex subunit mu  + + – 
Q96QR8 PURB Transcriptional activator protein Pur-beta  + + – 
Q96T37 RBM15 Putative RNA-binding protein 15  + + – 
Q9HCE1 MOV10 Putative helicase MOV-10  + + – 
Q9HCM4 E41L5 Band 4.1-like protein 5  + + – 
Q9NWB6 ARGL1 Arginine and glutamate-rich protein 1  + + – 
Q9NX58 LYAR Cell growth-regulating nucleolar protein  + + – 
Q9NZN8 CNOT2 CCR4-NOT transcription complex subunit 2  + + – 
Q9UG63 ABCF2 ATP-binding cassette sub-family F member 2  + + – 
Q9UKZ1 CNO11 CCR4-NOT transcription complex subunit 11  + + – 
Q9UQ35 SRRM2 Serine/arginine repetitive matrix protein 2  + + – 
Q9Y285 SYFA Phenylalanine--tRNA ligase alpha subunit  + + – 
Q9Y5A9 YTHD2 YTH domain family protein 2  + + – 
P17987 TCPA T-complex protein 1 subunit alpha  – + + 
P84090 ERH Enhancer of rudimentary homolog  – + + 
Q00325 MPCP Phosphate carrier protein mitochondrial  – + + 
Q15366 PCBP2 Poly(rC)-binding protein 2  – + + 
Q969G3 SMCE1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1  – + + 
P22087 FBRL rRNA 2'-O-methyltransferase fibrillarin  + – + 
P61962 DCAF7 DDB1- and CUL4-associated factor 7  + – + 
Q13347 EIF3I Eukaryotic translation initiation factor 3 subunit I  + – + 
Q9BUT9 F195A Protein FAM195A  + – + 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q9H0A0 NAT10 N-acetyltransferase 10  + – + 
O00571 DDX3X ATP-dependent RNA helicase DDX3X  + + + 
O15027 SC16A Protein transport protein Sec16A  + + + 
O75330 HMMR Hyaluronan mediated motility receptor  + + + 
P05141 ADT2 ADP/ATP translocase 2  + + + 
P06730 IF4E Eukaryotic translation initiation factor 4E  + + + 
P06753 TPM3 Tropomyosin alpha-3 chain  + + + 
P08107 HSP71 Heat shock 70 kDa protein 1A/1B  + + + 
P11940 PABP1 Polyadenylate-binding protein 1  + + + 
P16989 YBOX3 Y-box-binding protein 3  + + + 
P23246 SFPQ Splicing factor proline- and glutamine-rich  + + + 
P25705 ATPA ATP synthase subunit alpha mitochondrial  + + + 
P26196 DDX6 Probable ATP-dependent RNA helicase DDX6  + + + 
P26599 PTBP1 Polypyrimidine tract-binding protein 1  + + + 
P27348 1433T 14-3-3 protein theta  + + + 
P35251 RFC1 Replication factor C subunit 1  + + + 
P36542 ATPG ATP synthase subunit gamma mitochondrial  + + + 
P43243 MATR3 Matrin-3  + + + 
P51114 FXR1 Fragile X mental retardation syndrome-related protein 1  + + + 
P51116 FXR2 Fragile X mental retardation syndrome-related protein 2  + + + 
P52907 CAZA1 F-actin-capping protein subunit alpha-1  + + + 
P63167 DYL1 Dynein light chain 1 cytoplasmic  + + + 
P63244 GBLP Guanine nucleotide-binding protein subunit beta-2-like 1  + + + 
P67809 YBOX1 Nuclease-sensitive element-binding protein 1  + + + 
 
 
96 
UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
P67936 TPM4 Tropomyosin alpha-4 chain  + + + 
Q01844 EWS RNA-binding protein EWS  + + + 
Q04637 IF4G1 Eukaryotic translation initiation factor 4 gamma 1  + + + 
Q06787 FMR1 Fragile X mental retardation protein 1  + + + 
Q07666 KHDR1 KH domain-containing RNA-binding signal transduction-associated protein 1  + + + 
Q08211 DHX9 ATP-dependent RNA helicase A  + + + 
Q12905 ILF2 Interleukin enhancer-binding factor 2  + + + 
Q12906 ILF3 Interleukin enhancer-binding factor 3  + + + 
Q13283 G3BP1 Ras GTPase-activating protein-binding protein 1  + + + 
Q13310 PABP4 Polyadenylate-binding protein 4  + + + 
Q13501 SQSTM Sequestosome-1  + + + 
Q14004 CDK13 Cyclin-dependent kinase 13  + + + 
Q14444 CAPR1 Caprin-1  + + + 
Q15007 FL2D Pre-mRNA-splicing regulator WTAP  + + + 
Q15717 ELAV1 ELAV-like protein 1  + + + 
Q3MHD2 LSM12 Protein LSM12 homolog  + + + 
Q6PKG0 LARP1 La-related protein 1  + + + 
Q7Z417 NUFP2 Nuclear fragile X mental retardation-interacting protein 2  + + + 
Q86U86 PB1 Protein polybromo-1  + + + 
Q8NC51 PAIRB Plasminogen activator inhibitor 1 RNA-binding protein  + + + 
Q8TAQ2 SMRC2 SWI/SNF complex subunit SMARCC2  + + + 
Q8WWM7 ATX2L Ataxin-2-like protein  + + + 
Q92499 DDX1 ATP-dependent RNA helicase DDX1  + + + 
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UniProtKB 
Accession 
Number 
UniProtKB 
Symbol Protein Name MCF-7 C1 ΔCD 
Q92804 RBP56 TATA-binding protein-associated factor 2N  + + + 
Q92841 DDX17 Probable ATP-dependent RNA helicase DDX17  + + + 
Q99700 ATX2 Ataxin-2  + + + 
Q9BX70 BTBD2 BTB/POZ domain-containing protein 2  + + + 
Q9C0C2 TB182 182 kDa tankyrase-1-binding protein  + + + 
Q9H4H8 FA83D Protein FAM83D  + + + 
Q9NYF8 BCLF1 Bcl-2-associated transcription factor 1  + + + 
Q9NZB2 F120A Constitutive coactivator of PPAR-gamma-like protein 1  + + + 
Q9UN86 G3BP2 Ras GTPase-activating protein-binding protein 2  + + + 
Q9Y224 CN166 UPF0568 protein C14orf166  + + + 
Q9Y2W1 TR150 Thyroid hormone receptor-associated protein 3  + + + 
Q9Y3I0 RTCB tRNA-splicing ligase RtcB homolog  + + + 
Q9Y520 PRC2C Protein PRRC2C  + + + 
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